Genetic polymorphisms of the interleukin 23 receptor and interleukin 17A and their associations with inflammatory bowel diseases by 源��듅�썝
Genetic polymorphisms of the interleukin 23 
receptor and interleukin 17A and their 
associations with inflammatory bowel diseases 
 
 
 
 
 
 
 
 
 
 
 
Seung Won Kim 
Department of Medical Science 
The Graduate School, Yonsei University 
Genetic polymorphisms of the interleukin 23 
receptor and interleukin 17A and their 
associations with inflammatory bowel diseases 
 
 
 
 
 
 
 
 
 
 
 
Seung Won Kim 
Department of Medical Science 
The Graduate School, Yonsei University 
Genetic polymorphisms of the interleukin 23 
receptor and interleukin 17A and their 
associations with inflammatory bowel diseases 
 
 
Directed by Professor Won Ho Kim 
 
The Doctoral Dissertation 
submitted to the Department of Medical Science, 
the Graduate School of Yonsei University 
in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy of Medical Science 
 
Seung Won Kim 
 
December 2010 
This certifies that the Doctoral 
Dissertation of Seung Won Kim is 
approved. 
 
--------------------------------------------------------------------- 
Thesis Supervisor: Won Ho Kim 
 
--------------------------------------------------------------------- 
Thesis Committee Member#1: Jae Hee Cheon 
 
--------------------------------------------------------------------- 
Thesis Committee Member#2: Jeon Han Park 
 
--------------------------------------------------------------------- 
Thesis Committee Member#3: Chae Ok Yun 
 
--------------------------------------------------------------------- 
Thesis Committee Member#4: Seung Woo Park 
 
 
The Graduate School 
Yonsei University 
December 2010 
ACKNOWLEDGEMENTS 
학문의 배려와 가르침을 주신 김원호 교수님, 천재희 
교수님께 깊은 감사드립니다. 논문을 마치기까지 세심한 
지도와 조언을 아끼지 않으신 박전한 교수님, 저의 
부족함을 따끔한 충고와 질책으로 채워주신 윤채옥 
교수님과 박승우 교수님께도 감사드립니다. 격려와 더불어 
많은 힘이 되어 주신 교실 선생님들께도 감사의 말씀을 
전합니다. 그리고 힘들 때 위로와 힘이 되어준 여러 학우 
및 동료들에게도 고마움을 전합니다. 지난 시간 동안의 
즐거운 추억들은 가슴 깊이 오랫동안 간직 될 것 같습니다. 
오늘의 제가 있기까지 지켜봐 주시고 격려해주신 
가족분들께 고개숙여 감사드립니다. 사랑과 헌신으로 
키워주신 어머님, 든든한 의지가 되어준 형, 사랑스러운 
동생, 그리고 보이지 않는 곳에서 항상 지켜봐 주신 
아버님께 작지만 이 결실을 바칩니다. 
 
 
2010년 12월 
김승원 올림.
i 
 
<TABLE OF CONTENTS> 
 
ABSTRACT․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․1 
I. INTRODUCTION․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․4 
II. MATERIALS AND METHODS․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․7 
1. Study Subjects․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․7 
2. DNA Extraction and Polymerase Chain Reaction (PCR)․․․․․․․․․․․․․․8 
3. Genotyping․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․10 
4. Colonic Mucosal Tissue Preparation, Peripheral Blood Mononuclear Cell 
(PBMC) Isolation and Cell Culture․․․․․․․․․․․․․․․․․․․․․․․․․․․․․13 
5. Electrophoretic Mobility Shift Assay (EMSA)․․․․․․․․․․․․․․․․․․․․․14 
6. Quantitative Real-time Reverse-Transcription Polymerase Chain Reaction 
(RT-PCR)․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․16 
7. Determination of DNA Methylation using Bisulfate Sequencing and 
Pyrosequencing․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․17 
8. Statistical Analysis․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․19 
III. RESULTS․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․20 
1. Baseline Clinical Characteristics of Study Subjects․․․․․․․․․․․․․․․․․22 
ii 
 
2. Association of IL-23R Genetic Polymorphisms with IBD Susceptibility․20 
3. Associations of IL-17A Genetic Polymorphisms with IBD Susceptibility․24 
4. Haplotypes, Gene-gene Interaction and Risk of IBD․․․․․․․․․․․․․․․․27 
5. Allelic-specific Binding Activities of Nuclear Proteins in the IL-17A 
Promoter Region and their Effects on Gene Expression․․․․․․․․․․․․․43 
6. Associations of Aberrant Hypomethylation Status of IVS1+18 of IL-17A 
and Implication in IBD․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․50 
7. Association of IL-17A Silencing with DNA Methylation in Jurkat cells․57 
IV. DISCUSSION․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․60 
V. CONCLUSION․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․71 
REFERENCES․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․72 
ABSTRACT(IN KOREAN)․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․82 
 
 
 
 
iii 
 
LIST OF FIGURES 
 
Figure 1. Schematic representation of genotyping strategies for the 
IL-17A and IL-23R genes․․․․․․․․․․․․․․․․․․․․․․․․11 
Figure 2. Representative DHPLC elution profiles for SNPs in the IL-
23R gene․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․13 
Figure 3. Genetic analysis of IL-23R and IL-17A in IBD․․․․․․․․28 
Figure 4. Expressions of IL-17A mRNA in the colonic mucosa of 
IBD patients․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․43 
Figure 5. Structure of the putative human IL-17A promoter․․․․․․45 
Figure 6. Preferential binding of the transcription factor complex to 
the risk alleles of IL-17A․․․․․․․․․․․․․․․․․․․․․․․․․47 
Figure 7. Analysis of IL-17A mRNA expression in PBMCs from 
IBD patients․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․49 
Figure 8. Promoter methylation status of the IL-17A promoter in 
IBD patients․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․52 
Figure 9. Representative bisulfite sequencing and pyrosequencing 
iv 
 
data for quantitation of methylated CpGs in the IL-17A 
promoter in patient PBMC․․․․․․․․․․․․․․․․․․․․․․․54 
Figure 10. STAT4 mRNA expression and promoter methylation 
status of STAT4 promoter in patients with IBD․․․․․․․56 
Figure 11. IL-17A is downregulated via DNA methylation in Jurkat 
cell lines․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․57 
Figure 12. IL-17A methylation status in Jurkat cells․․․․․․․․․․․․59 
Figure 13. Proposed model depicting the interplay of the 
polymorphic sites in IL-23R and IL-17A gene in response 
to IL-23 mediated signals․․․․․․․․․․․․․․․․․․․․․․․․69 
v 
 
LIST OF TABLES 
 
Table 1. Oligonucleotides for genotyping of the IL-17A and IL-23R 
gene․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․9 
Table 2. Oligonucleotides for EMSA․․․․․․․․․․․․․․․․․․․․․․․15 
Table 3. Oligonucleotides for real-time RT-PCR․․․․․․․․․․․․․․17 
Table 4. Oligonucleotides for pyrosequencing and bisulfate 
sequencing of the IL-17A gene․․․․․․․․․․․․․․․․․․․․․18 
Table 5. Oligonucleotides for pyrosequencing and bisulfate 
sequencing of the STAT4 gene․․․․․․․․․․․․․․․․․․․․․18 
Table 6. Clinical and demographic characteristics of CD and UC 
Patients․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․21 
Table 7. Distribution of genotype and allele frequencies of IL-23R 
SNPs․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․23 
Table 8. Distributions of genotype and allele frequencies of IL-17A 
SNPs․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․24 
Table 9․ Haplotype Frequencies of IL-23R among cases and 
vi 
 
controls and their association with IBD․․․․․․․․․․․․․30 
Table 10․ Synergistic Interactions between IL-23R and IL-17A 
genotypes in UC․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․32 
Table 11. Synergistic Interactions between IL-23R and IL-17A 
genotypes in CD․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․27 
Table 12. Gene-gene interactions between IL-23R and STAT4 
genotypes in UC․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․34 
Table 13. Gene-gene interactions between IL-17A and STAT4 
genotypes in CD․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․36 
Table 14. Gene-gene interactions between IL-17A and STAT4 
genotypes in UC․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․․40 
 
1 
 
ABSTRACT 
 
Genetic polymorphisms of the interleukin 23 receptor and interleukin 17A 
and their associations with inflammatory bowel diseases 
 
Seung Won Kim 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Won Ho Kim) 
 
 
Inflammatory bowel disease (IBD), which includes mainly ulcerative colitis 
(UC) and Crohn‟s disease (CD), is characterized by chronic relapsing intestinal 
inflammation. Currently, IBD is considered to be caused by a complex 
interaction of genetic, environmental, and other processes involving 
immunoregulatory factors of which play a principal role in the pathogenesis of 
IBD. Recently, a particular subset of T helper cells (Th17 cells) characterized 
by interleukin 17A (IL-17A or further referred to as IL-17) production was 
implicated as a critical mediators of autoimmune disease including IBD and the 
2 
 
IL-23R gene is known to be a susceptibility gene related to IBD in Caucasian 
IBD patients, although it has not been detected in Asian populations. Moreover, 
while there are a few reports on the associations of IL-17A gene polymorphisms, 
it is still unknown whether IL-17A SNPs are associated with IBD susceptibility 
except rs2275913 and, if so, how these IL-17A SNPs exactly modulate IBD 
susceptibility. 
Thus, It was investigated the associations of genetic and epigenetic variations 
in IL-23R and IL-17A with the development of IBD in this study. The promoters 
and exon regions encompassing the intron junctions of IL-23R and IL-17A were 
analyzed in 728 subjects including 201 CD patients, 268 UC patients, and 259 
healthy controls using DNA sequencing and denaturing high performance liquid 
chromatography. Associations of IL-23R and IL-17A polymorphisms with IBD 
susceptibility were analyzed and their gene-gene interactions including STAT4 
SNPs were tested using logistic regression analysis. Jurkat cells and peripheral 
blood mononuclear cells (PBMC) were used for in vitro assay as follows. The 
transcription factor binding activity was determined using electrophoretic 
mobility shift assay, IL-17A mRNA expression levels by reverse-transcriptase 
polymerase chain reaction, and methylation status of IL-17A promoter by 
bisulfite sequencing and pyrosequencing.  
In CD, a case-control analysis showed that disease development was 
associated with the IL-23R variant G149R (odds ratios [OR] 0.32, 95% 
confidence intervals [CI] 0.15–0.68) and IL-17A variant IVS1+18G>C (OR 
3 
 
10.65, 95% CI 1.32–85.89). The analysis for UC showed an association with 
IL-23R variants G149R (OR 0.41, 95% CI 0.21–0.76), IVS4+17C>T (OR 2.89, 
95% CI 1.20–6.96), and Q3H (OR 0.61, 95% CI 0.38-0.99), and IL-17A 
variants -737C>T (OR 1.50, 95% CI 1.06–2.13), -197G>A (OR 0.63, 95% CI 
0.40–0.97), and IVS1+18 G>C (OR 8.93, 95% CI 1.12–70.99). As further 
evidence of the synergistic effect of the genes in this pathway in the 
development of IBD, a significant statistical gene-gene interaction among IL-
23R, IL-17A and STAT4 were observed. The -877G, -737T, and -444A risk 
alleles of IL-17A displayed higher binding affinity of transcription factor 
complex and higher expression levels of IL-17A transcripts. DNA 
hypomethylation of the IL-17A promoter was observed in PBMCs from IBD 
patients with a methylation extent of IVS1+17 site and significant inverse 
correlation between IL-17A mRNA level. Finally, IL-17A mRNA expression 
was restored after exposure to demethylating agent in Jurkat cells. The results 
of this study provide insights into the genetic and epigenetic interactions in the 
IL-23R/IL-17 axis including STAT4 that are associated with elevated expression 
of IL-17 and IBD pathogenesis. 
------------------------------------------------------------------------------------------------ 
Key words : interleukin 23 receptor, interleukin 17A, genetic polymorphism, inflammatory 
bowel disease, epigenetics 
4 
 
Genetic polymorphisms of the interleukin 23 receptor and interleukin 17A 
and their associations with inflammatory bowel diseases 
 
Seung Won Kim 
 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Won Ho Kim) 
 
 
 
I. INTRODUCTION 
 
Inflammatory bowel disease (IBD), which includes mainly ulcerative colitis (UC) and 
Crohn‟s disease (CD) is characterized by chronic relapsing intestinal inflammation of 
unknown etiology.
1
 Currently, IBD is considered to be caused by complex interactions 
of genetic, environmental, and other processes involving immunoregulatory factors.
2,3
 
Of these, studies in twins and family members suggest that genetic factors play a 
principal role in the pathogenesis of IBD. Recently, several IBD susceptibility genes 
5 
 
have been identified,
4
 and linkage studies have implicated multiple regions within the 
human genome.
5,6
 Since the caspase-recruitment domain 15 gene (NOD2) was 
identified as the first CD susceptibility gene in 2001, genome-wide association studies 
or linkage analyses uncovered several susceptibility genes related to IBD in Caucasian 
populations including DLG5, SLC22A4, SLC22A5, TNFSF15, IL-23R, and 
ATG16L1.
4,7-10
 However, the genetic polymorphisms located within these genes do not 
fully explain the pathogenesis of IBD or the variations in disease phenotypes. 
Furthermore, the precise genetic pathogenesis of IBD still remains poorly understood. 
Recently, a subset of T helper cells (Th17 cells) characterized by interleukin 17A (IL-
17A or further referred to as IL-17) production was implicated as a critical mediator of 
autoimmune diseases such as bronchial asthma, experimental autoimmune 
encephalomyelitis (EAE), rheumatoid arthritis (RA), psoriasis, systemic lupus 
erythematosus (SLE), systemic sclerosis (SSc), and IBD.
11-13
 Accumulating evidence 
has demonstrated that IL-17 plays an important pathologic role in the development of 
IBD.
13-15
 
Interleukin 23 (IL-23) is essential for maintaining the Th17 response
12
 and is 
characteristically associated with Th17 cell lineage differentiation.
16,17
 Moreover, IL-23 
receptors (IL-23Rs) are expressed on a variety of cells and may directly activate a 
subset of macrophages, natural killer cells, monocytes, and dendritic cells that secrete 
IL-17A.
18,19
 Interestingly, although the IL-23R gene is known to be a susceptibility 
gene related to IBD, functional variants in the IL-23R gene, which was identified as a 
susceptibility locus in Caucasian IBD patients, has not been detected in Asian 
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populations.
10,20-23
 These results reveal that there are distinct ethnic differences in the 
genetic background of IBD between Asian and Caucasian populations. Therefore, it is 
necessary to identify new functional variation in coding region of IL-23R in Asian 
patients with IBD. Moreover, while there are a few reports on the associations of IL-
17A gene polymorphisms with several autoimmune diseases such as RA and bronchial 
asthma,
24,25
 it is still unknown whether IL-17A SNPs (single nucleotide polymorphism) 
with the exception of rs2275913 are associated with IBD susceptibility and, if so, how 
these IL-17A SNPs exactly modulate IBD susceptibility. In another side, STAT4 (signal 
transducer and activator of transcription 4) is another critical transcription factor 
transducing IL-12-, IL-23-, and type-1 interferon (IFN)-mediated signals into Th1 and 
Th17 differentiation, monocyte activation, and IFN-production.
26-29
 STAT4 
polymorphisms have been found to be associated with autoimmune diseases, including 
IBD, RA, SLE, asthma, and Sjögren‟s syndrome (SS).30-33 IL-23 activates not only 
STAT3 but also to a lesser degree STAT4. STAT4 is also required for cytokine-
stimulated production of IL-17. Moreover, evidence for weak gene-gene interaction of 
STAT4 with the IL-23R SNPs in Caucasian was recently reported.
34
 
In this study, the roles of IL-23R and IL-17A SNPs in the genetic susceptibility to IBD 
in the Korean population were assessed to elucidate their association with IBD. 
Potential epistasis (gene-gene interaction) among the IBD susceptibility gene IL-23R, 
IL-17A and STAT4 was next investigated. It was also investigated the functional 
consequences of genetic and epigenetic factors that interact to increase the 
susceptibility to IBD . 
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II. MATERIALS AND METHODS 
 
1. Study Subjects  
A total of 258 healthy controls, and 469 unrelated Korean IBD participants (201 
patients with CD, 268 with UC) were surveyed, and IBD patients were diagnosed and 
managed at the gastroenterology clinics of Yonsei University College of Medicine, 
Severance Hospital, Seoul, Korea between June 2006 and February 2008. The 
diagnosis of CD or UC was based on established clinical, radiologic, endoscopic, and 
histopathologic criteria.
35,36
 Cases of indeterminate colitis, or patients with 
concomitant immune-mediated diseases such as RA, SLE, primary SS, type 1 
diabetes, SSc, or asthma were excluded from the study. The demographic and clinical 
characteristics of the subjects were obtained through the review of medical records 
and detailed questionnaires. CD phenotypes were classified by age at diagnosis, 
location, and disease behavior according to the Montreal classification.
37
 In patients 
with UC, anatomic locations were subgrouped using the Montreal classification as 
ulcerative proctitis (E1), left-sided UC (E2) or extensive UC (E3). Differences in the 
frequencies of disease characteristics such as age at diagnosis, gender, extra-intestinal 
manifestations (EIMs), total follow-up period, the use of immunosuppressive drugs, 
and the need for surgical intervention were also assessed. This study was approved by 
the Institutional Review Board of Severance Hospital. Written informed consent was 
obtained from all participants or their guardians. 
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2. DNA Extraction and Polymerase Chain Reaction (PCR) 
Genomic DNA was isolated from whole blood samples from each subject using 
commercially available kits (Qiagen, Hilden, Germany). Specific primers were 
designed to amplify the promoter and exons spanning splice junctions (Table 1). 
9 
 
Table 1. Oligonucleotides for genotyping of the IL-17A and IL-23R genes 
Target gene Regions Forward sequence Reverse sequence 
IL-17A 
Promoter 4 TTCAGGATCCGGCAAACTAAT GATAGAGACTGGACAAAGGTG 
Promoter 3 CCATCATGTTCCTCTCCTT CCTCACAGATTCCTTGGCC 
Promoter 2 TTGAGTAGTTTCCGGAATTGTC TGTCGCAGTGGGTTCAGGG 
Promoter 1 
~ exon 1 
ACATGAATTTCTGCCCTTCCC CCACGGTCCAGAAATACTATC 
Exon 2 AACCACATAGTAATCTAATCTCC GATGCATAAGAGGGATGAAGAAT 
Exon 3 CTCTCTTCATGTATTCCTGTTT GGATGAGGGTTCCTGAGGG 
IL-23R 
Exon 1 CCAAATAGTGACACGAGAGCCAG AACAACTTGGCCCATGTATTTCC 
Exon 2 CCCTAATCAAAGGTTCCCATC CATTTGGAAGGAGATTGGGC 
Exon 3 TCTTCTGAATCTCTTGATTTAATGTTT TGACCAGTTAATTGTTAAACTAGC 
Exon 4 GACTGGAGCTGTTCCTATTCAGC GATTTCTTGGATCTCTGCTGGAGG 
Exon 5 GAGCCACCATGCCTGGCCAATTA AGACCTCATTTGACAAGGTCAGCA C 
Exon 6 TGCCAGTTTCTCCCTAGGCAAGT AAATAGACATAATAAGTCCACTGTAGCC 
Exon 7 GGTGTTCCATACATTTCTGCTAA ATTATAGGTGTGAGCCACTGTGC 
Exon 8 CAAGGGAAGAAACTCCGTTGGGA CCTATGGAAGACATAAGGCATATC 
Exon 9 CACCCTTTCTCCTTTGAGACCT TCTAGTAAACAACTGAAATGACTAAAT 
Exon 10 AATCCTCCCACCTCAGCC TGATTTGAAACAGGTACAGTTTTG 
Exon 11-1 TCATTCAATTATCCAGTTGGTTC TATTGCTGAGATGGCTTCCC 
Exon 11-2 GAGACTACCCGCAAAACTCG ATTTTCCAAAAGCATGGTGG 
Exon 11-3 TGAATTCACTAAGCAACACAATATTTC GATTGCAAGGCAGCTTTCTC 
10 
 
Genotyping was performed using PCR. PCR was carried out in a total volume of 
25 µl containing 200 M dNTPs, 50 ng of template DNA, 10 pmol of each primer, 
and 0.5 unit of i-StarmaxTM II DNA Taq Polymerase (Intron Biotechnology, Seoul, 
Korea) in 1  reaction buffer. The PCR was performed with an initial denaturation 
step at 94°C for 5 min; 35 cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 
30-90 sec; and a final extension step at 72°C for 7 min. 
 
3. Genotyping 
DNA sequencing was used for preliminary identification of candidate IBD risk 
SNPs of IL-23R in 50 patients and 50 controls; all the remaining subjects enrolled in 
the study were genotyped using full DNA sequencing of promoter regions and 
denaturing high performance liquid chromatography (DHPLC) of exons and all splice 
junctions (Figure 1).  
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Figure 1. Schematic representation of the genotyping strategies for the IL-17A and IL-
23R genes. The genomic region of the human IL-17A gene encompassing the 
promoter and three exons and that of the IL-23R gene encompassing 11 exons are 
schematically shown. +1 indicates the first nucleotide of the start codon. Coding 
exons are marked by filled blocks and untranslated regions (UTR) by open blocks. 
Filled circles show the primer sites. 
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After purification using a PCR purification kit (Qiagen), the PCR products were 
used as template DNA for sequencing analysis (ABI Prism Big Dye Terminator cycle 
sequencing system; ABI 3100 automatic sequencer, Applied Biosystems, Foster City, 
CA, USA). Unpurified PCR products were mixed 3:1 with a sequence-confirmed 
wild-type reference before being subjected to a 5 min, 95°C denaturing step, followed 
by gradual cooling to 65°C with a temperature change of 1°C/min before DHPLC 
analysis. The addition of wild-type DNA to the sample before the denaturation step 
enabled reliable detection of homozygous alteration to identify homozygous 
sequence variations. Five microliters of each mixture were loaded onto a DNASep-
HT column (Transgenomic, Omaha, NE, USA) and the amplicons were eluted in 0.1 
M triethylammonium acetate (pH 7) with a linear acetonitrile gradient at a flow rate 
of 1.5 ml/min. Heteroduplex mismatches were recognized by the appearance of 
aberrant patterns in the elution profiles under appropriate temperature conditions, 
which were calculated by the Navigator Software of the Wave Nucleic Acid Fragment 
Analysis system device (Transgenomic). The most important criteria for assigning the 
presence of a sequence alteration in each DHPLC fragment were numbered and the 
shapes of the elution peaks compared to a sequence-confirmed wild-type control 
subject elution profiles that were used as references (Figure 2). All detected variations 
from DHPLC analysis were validated using subsequent full DNA sequencing. 
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Figure 2. Representative DHPLC elution profiles for SNPs in the IL-23R gene. Seven 
SNPs were found in intron 1, exon 2, exon 4, and intron 4. From top to bottom and 
left to right, each peak shows the absorbance and elution time, respectively. 
 
 
The genotype data for eight IBD-associated STAT4 SNPs (rs11889341, 
rs7574865, rs8179673, rs6752770, rs925847, rs10168266, rs10181656, 
rs11685878) were available from a previous study.
30
 
 
4. Colonic Mucosal Tissue Preparation, Peripheral Blood Mononuclear Cell 
(PBMC) Isolation and Cell Culture 
Colonic mucosal tissues were collected during colonoscopy and PBMCs were 
isolated using Ficoll-paque plus density gradient centrifugation (GE Health Care, 
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Piscataway, NJ, USA) from healthy donors and IBD patients. Jurkat cells 
(American Type Culture Collection, Manassas, VA, USA) were cultured in RPMI 
1640 medium supplemented with 10% fetal bovine serum, 1 mM glutamine and 1% 
penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). Jurkat cells at a density of 
0.5-1.0  106 cells/ml were then activated with anti-CD3 mAb (2 μg/ml; eBioscience, 
San Diego, CA, USA) and anti-CD28 mAb (1 μg/ml; eBioscience) for four days, and 
were stimulated with tumor growth factor β (TGF-β; 2.5 ng/ml; R&D Systems, 
Minneapolis, MN, USA), IL-6 (30 ng/ml; R&D Systems), IL-23 (10 ng/ml; R&D 
Systems), or with phorbol 12-myristate 13-acetate (PMA, 20 nM; Sigma-Aldrich St. 
Louis, MO, USA) and ionomycin (2 μM; Sigma-Aldrich) for six h. To assess re-
activation of IL-17A expression, Jurkat cells were plated in 6-well tissue plates 16 hr 
before treatment, 5-azadeoxycytidine (5-Aza-dC; Sigma-Aldrich) at final 
concentrations of 0.4 μM or phosphate buffered saline in duplicate was added to the 
fresh medium and the cells were harvested after three or four days of treatment.  
 
5. Electrophoretic Mobility Shift Assay (EMSA) 
Nuclear and cytoplasmic extracts were prepared as follows. Briefly, harvested cells 
were lysed for 5 min in lysis buffer [5 mM KCl, 25 mM HEPES, 0.5 mM MgCl2, 1 
mM EDTA, 0.5 mM spermidine, 0.15 mM spermine, 0.2% Triton X-100, complete 
protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany)], and then 
nuclei were pelleted via centrifugation at 6,000 g for 15 min. Nuclei were lysed in 
hypotonic buffer (350 mM NaCl, 10 mM HEPES, 25% glycerol, 0.1 mM EDTA, 0.5 
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mM spermidine, 0.15 mM spermine, and protease inhibitors as above) for 30 min, 
and debris were removed via centrifugation at 13,000 rpm for 5 min. Bradford 
reagent (Bio-Rad Laboratories, Hercules, CA, USA) was used to measure protein 
content. EMSA was performed using a Lightshift
TM
 chemiluminiscent EMSA kit 
(Pierce, Rockford, IL, USA) following the manufacturer‟s protocol. Complementary 
oligonucleotides (Table 2) were biotin-labeled separately using the Biotin End-
labeling kit (Pierce) and annealed before use.  
 
 
Table 2. Oligonucleotides for EMSA 
Region Sense sequence Antisense sequence 
-877- 
wild type 
CTATTCTCAAGGACCTGAGTCCAAG CTTGGACTCAGGTCCTTGAGAATAG 
-877- 
mutant type 
CTATTCTCGAGGACCTGAGTCCAAG CTTGGACTCAGGTCCTCGAGAATAG 
-737- 
wild type 
CCTTTTCTCCATCTCCATCACCTTTGTC GACAAAGGTGATGGAGATGGAGAAAAGG 
-737- 
mutant type 
CCTTTTCTCCATCTTCATCACCTTTGTC GACAAAGGTGATGAAGATGGAGAAAAGG 
-444- 
wild type 
AGGAATCTGTGAGGAAAAGAAAGATCAA TTGATCTTTCTTTTCCTCACAGATTCCT 
-444- 
mutant type 
AGGAATCTGTGAGGGAAAGAAAGATCAA TTGATCTTTCTTTCCCTCACAGATTCCT 
-197- 
wild type 
CCTTCAGAAGGAGAGATTCTTCTATGA TCATAGAAGAATCTCTCCTTCTGAAGG 
-197- 
mutant type 
CCTTCAGAAGAAGAGATTCTTCTATGA TCATAGAAGAATCTCTTCTTCTGAAGG 
The oligonucleotides of IL-17A promoter regions with the normal or variant sequence for 
SNPs were used as probe. Complementary oligonucleotides were biotin-labeled separately 
and annealed before use. The variation sequences are underlined.
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Each binding reaction contained 1  binding buffer (100 mM Tris, pH 7.5, 500 mM 
KCl, 10 mM dithiothreitol), 2.5% glycerol, 5 mM MgCl2, 50 ng/μl poly (dIdC), 
0.05% NP-40, 5 g of nuclear extract, and 40 fM of biotin end-labeled target 
oligonucleotide probe. The reaction mixture was incubated at room temperature 
for 20 min, and the complexes were separated on 4% non-denaturing polyacrylamide 
gel and then were transferred to a nylon membrane. When the transfer was complete, 
DNA was crosslinked to the membrane at 120 mJ/cm
2
 using a UV crosslinker at 254 
nm. The biotin end-labeled DNA was detected using streptavidin-horseradish 
peroxidase conjugate and a chemiluminescent substrate. The membrane was exposed 
to X-ray film and developed using a Kodak film processor (Eastman Kodak, 
Rochester, NY, USA). RAR-related orphan receptor C (RORC) antibody (Abcam, 
Cambridge, MA, USA) was used for the supershift assay.  
 
6. Quantitative Real-time Reverse-transcription Polymerase Chain Reaction 
(RT-PCR) 
Total RNA was extracted using TRIzol Reagent (Invitrogen) and 1 μg of RNA was 
reverse transcribed using the SuperScript First-Strand Synthesis kit (Invitrogen) 
according to the manufacturer-recommended protocol. The cDNAs were mixed with 
SYBR Green master mix (Applied Biosystems) and the primer pairs (4 pmol of each 
primer) in triplicate. PCR was performed using primers (Table 3) for IL-17A, RORC, 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
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Table 3. Oligonucleotides for real-time RT-PCR 
Target Sense sequence Antisense sequence 
IL-17A CAATCCCACGAAATCCAGGATG GGTGGAGATTCCAAGGTGAGG 
RORC TTTTCCGAGGATGAGATTGC CTTTCCACATGCTGGCTACA 
STAT4 CACCTGCCACATTGAGTCAACTA TAAGACCACGACCAACGTACGA 
GAPDH TGATGACATCAAGAAGGTGG TTTCTTACTCCTTGGAGGCC 
 
 
Samples were amplified in a 7500 real-time PCR System (Applied Biosystems) for 
40-45 cycles using the following PCR variables: 95°C for 30 sec, 60-62°C for 1 min, 
and 72°C for 1 min. Finally, quantitative analysis was performed using the relative 
standard curve method and the results were reported as the relative expression or fold 
change as compared to that of the calibrator after normalization of the transcript level 
with regard to the control, namely GAPDH, or RORC. 
 
7. Determination of DNA Methylation using Bisulfate Sequencing and 
Pyrosequencing 
To determine the methylation status of CpG sequences in the IL-17A gene promoter, 
bisulfite modification was accomplished using an Epitect bisulfite kit (Qiagen) 
according to the manufacturer‟s instructions. The promoter region of the IL-17A gene 
from PBMCs was PCR-amplified with primers (Table 4 and 5) that were designed 
using a PSQ assay design program. 
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Table 4. Oligonucleotides for pyrosequencing and bisulfate sequencing of the IL-17A 
gene 
Application Regions Forward primer  Reverse primer 
1st PCR 
-969~-684 Biotin-ATTATTTATTTTAGTGGGGGTAGG ACCCTACATACTACCAAACAACTT 
-234~IVS1+77 Biotin-TGAAAAGAGGATATGGTTTTTAGG CCTAAATCTCCATAATCAAAACCC 
2nd PCR 
sequencing 
-969~-876 Biotin-ATTATTTATTTTAGTGGGGGTAGG ATAAACTTAAACTCAAATCC 
-234~IVS1+21 Biotin-TGAAAAGAGGATATGGTTTTTAGG CCAAATCAACAAAAACATC 
Pyrosequencing 
-877  ATAAACTTAAACTCAAATCC 
-2, IVS1+17, 
 IVS1+21 
 CCAAATCAACAAAAACATC 
 
Table 5. Oligonucleotides for pyrosequencing and bisulfate sequencing of the STAT4 
gene 
Application Regions Forward primer  Reverse primer 
PCR 
-266~-58 Biotin- GGTTGAGTGGAGTTTTATATTA TCTATTCTAAAAATACTAAC 
-176~ +49 Biotin- GGAAATTATTGAAGAAAATGTAT CCTAAATCTCCATAATCAAAACCC 
Pyrosequencing 
-266~-147  CAACTACAAATAACTCAAC 
-146~-58  TCTATTCTAAAAATACTAAC 
-57~-42  CCACTTAAAACTTTCCTATA 
-42~-+49  ACTCAAATCCAAAATCAA 
 
 
Bisulfite sequencing analyses were performed as described previously,
38
 and the 
pyrosequencing reactions were performed on a PyroMark Q24 system (Qiagen) 
following the manufacturer‟s instruction. The subsequent data were analyzed using 
the methylation-analysis software. 
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8. Statistical Analysis 
All SNPs investigated in this study were tested for Hardy-Weinberg equilibrium 
(HWE) in controls and associations of SNPs with disease susceptibility were 
determined by comparing allele and genotype frequencies between cases and controls 
using the Chi-square test. Logistic regression analyses were performed to calculate 
the odds ratios (OR), 95% confidence intervals (CI), and corresponding P-values of 
each SNP under four alternative models (additive, codominant, dominant, and 
recessive). In addition, relationships between disease genotypes and phenotypes were 
assessed according to clinical characteristics, such as mean age at diagnosis, gender, 
disease location and behavior, EIMs, and a history of immunosuppressive drug use 
and surgical intervention. 
Haploview software version 4.1 (Broad Institute of MIT and Harvard, Cambridge, 
MA, USA) was used to analyze the linkage disequilibrium (LD) structure and to test 
for associations between haplotypes and IBD. Haplotypes with a frequency > 3% 
were numbered in order of frequency (H1, H2, and so on). Gene–gene interactions 
were tested using an interaction test in logistic regression models.
39
 For all 
calculations, SPSS version 12.0 (SPSS, Chicago, IL, USA) was used. A two-tailed 
test was used for all analyses and two-sided P-values of < 0.05 were considered 
significant. 
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III. RESULTS 
 
1. Baseline Clinical Characteristics of the Study Subjects 
A total of 727 subjects including 201 patients with CD, 268 patients with UC, and 
258 healthy controls were analyzed in this study. The demographic and clinical 
characteristics of patients with CD and UC are summarized in Table 6. The mean 
patient age at diagnosis of CD was 26.0±11.2 years at a gender ratio ratio of 1.6:1 
(male: female), and that of UC was 36.4±12.4 years at a gender ratio of 1.0:1.0 Based 
on the Montreal Classification, 87.1% of CD patients had only ileal or ileocolonic 
disease, with or without upper gastrointestinal involvement. As for disease behavior, 
penetrating phenotype was observed in 78 (39.2%) patients and a stricturing 
phenotype in 37 (18.6%) patients. With respect to disease location at diagnosis in UC, 
extensive colitis was noted in 113 (42.1%) patients and left-sided colitis in 91 
(34.0%) patients. 
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Table 6. Clinical and demographic characteristics of CD and UC patients 
 CD (n = 201) UC (n = 268) 
Gender (male/female) 123/78 (1.6:1) 135/133 (1.0:1) 
Age (years)
a
 26.0±11.2 36.4±12.4 
Follow-up duration (months)
a
 89.3±51.7 103.6±61.3 
Disease location (%)
b
   
Ileum (L1)±L4 61 (30.7)  
Colon (L2)±L4 24 (12.1)  
Ileocolon (L3)±L4 114 (57.3)  
Rectum (E1)  64 (23.9) 
Left-side (E2)  91 (34.0) 
Extensive (E3)  113 (42.1) 
Disease behavior (%)
b
   
Inflammatory (B1)±p 81 (41.3)  
Stricturing (B2)±p 37 (18.6)  
Penetrating (B3)±p 78 (39.2)  
EIMs (%)   
Joint 19 (9.5) 30 (14.9) 
Skin 10 (5.0) 20 (10.0) 
Eye 11 (5.5) 28 (13.9) 
Immunosuppressive drugs   
Steroid 137 (68.2) 97 (51.7) 
Azathioprine 107 (53.2) 42 (20.9) 
Infliximab 36 (17.9) 1 (0.5) 
CD, Crohn‟s disease; UC, ulcerative colitis; EIMs, extra-intestinal manifestations. 
a
Mean±standard deviation. 
b
Disease localization and behavior according to the Montreal 
classification (L4, upper gastrointestinal involvement; p, perianal disease).
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2. Association of IL-23R Genetic Polymorphisms with IBD Susceptibility 
According to DHPLC and DNA sequencing of the exon regions including 
exon/intron junctions of IL-23R to uncover functional variations, seven SNPs in 
HWE(P > 0.05) was found, of which five (intron 1: IVS1-26G>C; exon 4: V134D, 
K150E, K160L; intron 4: IVS4+17C>T) had never been reported (Table 7). CD 
showed a significant association with one marker in exon 4, G149R (P < 0.002, 95% 
CI 0.15–0.68 in codominant models) and UC with three markers, rs1884444 (named 
“Q3H” hereafter) in exon 2 (P < 0.045, 95% CI 0.38–0.99 in recessive), G149R (P < 
0.004, 95% CI 0.21–0.77 in additive and dominant), and IVS4+17C>T (P < 0.012, 
95% CI 1.20–6.96 in codominant). G149R and Q3H showed a protective association 
and IVS4+17C>T was responsible for disease risk. The variant rs11209026 which 
was described to be responsible for CD in Caucasians, appears to be absent in the 
Korean population. 
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Table 7. Distributions of genotype and allele frequencies of IL-23R SNPs 
  CD UC Control 
  No.(%) Additive Codominant Dominant Recessive No. (%) Additive Codominant Dominant Recessive No. (%) 
Position Genotype  P value P value P value P value  P value P value P value P value  
(dbSNP ID)    
OR 
(95% CI) 
    
OR 
(95% CI) 
   
   
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
 
IVS1-26 GG 
199 
(99.0%) 
NA 
 
0.069 
 
NA 
 
NA 
 
268 
(100.0%) 
NA 
 
NA 
 
NA 
 
NA 
 
258 
(100.0%) 
(Novel) GC 
2 
(1.0%) 
 
NA 
(0.00-NA) 
  
0 
(0.0%) 
    
0 
(0.0%) 
 CC 
0 
(0.0%) 
    
0 
(0.0%) 
    
0 
(0.0%) 
Q3H GG 
70 
(34.8%) 
0.820 0.240 0.300 0.370 
107 
(39.9%) 
0.270 0.110 0.930 0.045 
102 
(39.5%) 
(rs1884444) GT 
100 
(49.8%) 
 
1.35 
(0.90-2.03) 
  
128 
(47.8%) 
 
1.13 
(0.78-1.64) 
  
108 
(41.9%) 
 TT 
31 
(15.4%) 
1.03 
(0.80-
1.34) 
0.94 
(0.55-1.62) 
1.22 
(0.83-
1.79) 
0.80 
(0.49-
1.31) 
33 
(12.3%) 
0.87 
(0.68-
1.11) 
0.66 
(0.39-1.10) 
0.98 
(0.69-
1.40) 
0.61 
(0.38-
0.99) 
48 
(18.6%) 
V134D TT 
200 
(99.5%) 
NA 0.260 NA NA 
262 
(97.8%) 
NA 0.056 NA NA 
254 
(98.5%) 
(Novel) TA 
1 
(0.0%) 
    
6 
(2.2%) 
 
1.45 
(0.41-5.21) 
  
4 
(1.6%) 
 AA 
0 
(0.0%) 
 
0.32 
(0.04-2.86) 
  
0 
(0.0%) 
    
0 
(0.0%) 
G149R GG 
192 
(95.5%) 
 
0002 
 
  
253 
(94.4%) 
 
0.004 
 
  
225 
(87.2%) 
 GA 
9 
(4.5%) 
 
0.32 
(0.15-0.68) 
  
15 
(5.6%) 
    
33 
(12.8%) 
 AA 
0 
(0.0%) 
    
0 
(0.0%) 
 
0.41 
(0.21-0.76) 
  
0 
(0.0%) 
K150E AA 
200 
(99.5%) 
NA 
 
0.200 
 
NA 
 
NA 
 
266 
(99.2%) 
NA 
 
0.100 
 
NA 
 
NA 
 
258 
(100.0%) 
(Novel) AG 
1 
(0.5%) 
 
NA 
(0.00-NA) 
  
2 
(0.8%) 
 
NA 
(0.00-NA) 
  
0 
(0.0%) 
 GG 
0 
(0.0%) 
    
0 
(0.0%) 
    
0 
(0.0%) 
K160L GG 
200 
(99.5%) 
NA 
 
0.200 
 
NA 
 
NA 
 
268 
(100.0%) 
NA 
 
NA 
 
NA 
 
NA 
 
258 
(100.0%) 
(Novel) GC 
1 
(.5%) 
 
NA 
(0.00-NA) 
  
0 
(0.0%) 
    
0 
(0.0%) 
 CC 
0 
(0.0%) 
    
0 
(0.0%) 
    
0 
(0.0%) 
IVS4+17 CC 
193 
(96.0%) 
 
0.450 
 
  
248 
(92.5%) 
 
0.012 
 
  
251 
(97.3.%) 
(Novel) CT 
8 
(4.0%) 
 
1.49 
(0.53-4.17) 
  
20 
(7.5%) 
    
7 
(2.7%) 
 TT 
0 
(0.0%) 
    
0 
(0.0%) 
 
2.89 
(1.20-6.96) 
  
0 
(0.0%) 
“Novel” indicates SNPs that had not been reported previously. Associations significant at P < 
0.05 are shown in bold. NA, Not applicable; IVS, intervening sequence.
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3. Associations of IL-17A Genetic Polymorphisms with IBD Susceptibility 
Based on DNA sequencing and DHPLC of the promoter and exon regions of IL-17A, 
14 SNPs in HWE from promoter regions was found, of which seven SNPs (-861G>A, 
-851C>G, -759C>G, -604delT, -265G>A, -168C>G, and -112G>A) had never been 
reported (Table 8).  
 
 
Table 8. Distributions of genotype and allele frequencies of IL-17A SNPs 
  CD UC Control 
  No. (%) Additive Codominant Dominant Recessive No. (%) Additive Codominant Dominant Recessive No. (%) 
Position† Genotype  P value P value P value P value  P value P value P value P value  
(dbSNP ID)    
OR 
(95% CI) 
    
OR 
(95% CI) 
   
   
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
OR 
(95% CI) 
 
-877 AA 
104 
(51.7%) 
0.170 
 
0.300 
 
0.340 
 
0.140 
 
131 
(48.9%) 
0.087 
 
0.220 
 
0.093 
 
0.370 
 
145 
(56.2%) 
(rs4711998) AG 
77 
(38.3%) 
 
1.10 
(0.75- 1.64) 
  
115 
(42.9%) 
 
1.30 
(0.92-1.88) 
  
97 
(37.6%) 
 GG 
20 
(9.9%) 
1.22 
(0.92-
1.63) 
1.74 
(0.86- 3.52) 
1.20 
(0.83-
1.73) 
1.67 
(0.84-
3.32) 
22 
(8.2%) 
1.27 
(0.96-
1.67) 
1.52 
(0.77-3.02) 
1.34 
(0.95-
1.89) 
1.35 
(0.69-
2.64) 
16 
(6.2%) 
-861 GG 
200 
(99.5%) 
NA 0.860 NA NA 
267 
(99.6%) 
NA .980 NA NA 
257 
(99.6%) 
(Novel) GA 
1 
(0.5%) 
 
1.28 
(0.08-
20.67) 
  
1 
(0.4%) 
 
0.96 
(0.06-
15.47) 
  
1 
(0.4%) 
 AA 
0 
(0.0%) 
    
0 
(0.0%) 
    
0 
(0.0%) 
-851 CC 
200 
(99.5%) 
NA 
 
0.2 
 
NA 
 
NA 
 
268 
(100.0%) 
NA 
 
NA 
 
NA 
 
NA 
 
258 
(100.0%) 
(Novel) CG 
1 
(0.5%) 
 
NA 
(0.00-NA) 
  
0 
(0.0%) 
    
0 
(0.0%) 
 GG 
0 
(0.0%) 
    
0 
(0.0%) 
    
0 
(0.0%) 
-759 CC 
201 
(100.0%) 
NA 
 
NA 
 
NA 
 
NA 
 
266 
(99.2%) 
NA 
 
.100 
 
NA 
 
NA 
 
258 
(100.0%) 
(Novel) CG 
0 
(0.0%) 
    
2 
(0.8%) 
 
NA 
(0.00-NA) 
  
0 
(0.0%) 
 GG 
0 
(0.0%) 
    
0 
(0.0%) 
    
0 
(0.0%) 
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Continued 
-737 CC 
106 
(52.7%) 
0.290 
 
0.420 
 
0.510 
 
0.200 
 
106 
(39.6%) 
0.033 
 
0.067 
 
0.020 
 
0.450 
 
128 
(49.6%) 
(rs8193036) CT 
84 
(41.8%) 
 
0.94 
(0.64- 1.38) 
  
134 
(50.0%) 
 
1.50 
(1.04-2.15) 
  
108 
(41.9%) 
 TT 
11 
(5.5%) 
0.85 
(0.63-1.15) 
0.60 
(0.28- 1.30) 
0.88 
(0.61-1.28) 
0.62 
(0.29-1.31) 
28 
(10.4%) 
1.34 
(1.02-1.74) 
1.54 
(0.83-2.84) 
1.50 
(1.06-2.13) 
1.25 
(0.70-2.25) 
22 
(8.5%) 
-604 TT 
201 
(100.0%) 
NA 
 
NA 
 
NA 
 
NA 
 
267 
(99.6%) 
NA 
 
0.250 
 
NA 
 
NA 
 
258 
(100.0%) 
(Novel) T- 
0 
(0.0%) 
    
1 
(0.4%) 
 
NA 
(0.00-NA) 
  
0 
(0.0%) 
 -- 
0 
(0.0%) 
    
0 
(0.0%) 
    
0 
(0.0%) 
-525 AA 
171 
(85.1%) 
0.190 
 
0.260 
 
0.240 
 
0.200 
 
227 
(84.7%) 
0.140 
 
0.230 
 
0.170 
 
0.250 
 
229 
(88.8.%) 
(rs9791323) AC 
29 
(14.4%) 
 
1.34 
(0.77- 2.32) 
  
40 
(14.9%) 
 
1.39 
(0.83-2.32) 
  
29 
(11.2%) 
 CC 
1 
(0.5%) 
1.42 
(0.83-2.42) 
NA 
(0.00-NA) 
1.39 
(0.80-2.40) 
NA 
(0.00-NA) 
1 
(.4%) 
1.45 
(0.88-2.39) 
NA 
(0.00-NA) 
1.43 
(0.86-2.37) 
NA 
(0.00-NA) 
0 
(0.0%) 
-444 AA 
47 
(23.4%) 
0.320 0.490 0.230 0.690 
80 
(29.9%) 
0.230 0.250 0.690 0.095 
73 
(28.3%) 
(rs3819024) AG 
108 
(53.7%) 
 
1.29 
(0.83-2.02) 
  
146 
(54.5%) 
 
1.02 
(0.69-1.52) 
  
130 
(50.4%) 
 GG 
46 
(22.9%) 
1.14 
(0.88-1.49) 
1.30 
(0.76-2.22) 
1.29 
(0.85-1.98) 
1.10 
(0.70-1.71) 
42 
(15.7%) 
0.86 
(0.67-1.10) 
0.70 
(0.42-1.16) 
0.93 
(0.64-1.35) 
0.69 
(0.44-1.07) 
55 
(21.3%) 
-265 GG 
200 
(99.5%) 
NA 
 
0.200 
 
NA 
 
NA 
 
268 
(100.0%) 
NA 
 
NA 
 
NA 
 
NA 
 
258 
(100.0%) 
(Novel) GA 
1 
(0.5%) 
 
NA 
(0.00-NA) 
  
0 
(0.0%) 
    
0 
(0.0%) 
 AA 
0 
(0.0%) 
    
0 
(0.0%) 
    
0 
(0.0%) 
-197 GG 
55 
(27.4%) 
0.690 
 
0.590 
 
0.390 
 
0.800 
 
90 
(33.6%) 
0.110 
 
0.110 
 
0.530 
 
0.036 
 
80 
(31.0%) 
(rs2275913) GA 
102 
(50.8%) 
 
1.25 
(0.81-1.92) 
  
136 
(50.8%) 
 
1.02 
(0.69-1.50) 
  
119 
(46.1%) 
 AA 
44 
(21.9%) 
1.05 
(0.81-1.36) 
1.08 
(0.64-1.82) 
1.19 
(0.79-1.79) 
0.95 
(0.61-1.47) 
420 
(15.7%) 
0.82 
(0.64-1.05) 
0.63 
(0.38-1.04) 
0.89 
(0.62-1.28) 
0.63 
(0.40-0.97) 
59 
(22.9%) 
-168 CC 
201 
(100.0%) 
NA 
 
.280 
 
NA 
 
NA 
 
268 
(100.0%) 
NA 
 
.230 
 
NA 
 
NA 
 
257 
(99.6%) 
(Novel) GC 
0 
(0.0%) 
    
0 
(0.0%) 
 
0.00 
(0.00-NA) 
  
1 
(0.4%) 
 GG 
0 
(0.0%) 
 
0.00 
(0.00-NA) 
  
0 
(0.0%) 
    
0 
(0.0%) 
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Continued 
-121 GG 
156 
(77.6%) 
0.630 
 
0.880 
 
0.610 
 
0.960 
 
198 
(73.9%) 
0.630 
 
0.890 
 
0.650 
 
0.780 
 
195 
(75.6%) 
(rs8193037) GA 
42 
(20.9%) 
 
0.89 
(0.57-1.39) 
  
65 
(24.2%) 
 
1.09 
(0.72-1.63) 
  
59 
(22.9%) 
 AA 
3 
(1.5%) 
0.91 
(0.61-1.35) 
0.94 
(0.21-4.25) 
0.89 
(0.58-1.39) 
0.96 
(0.21-4.35) 
5 
(1.9%) 
1.09 
(0.76-1.56) 
1.23 
(0.33-4.65) 
1.09 
(0.74-1.62) 
1.21 
(0.32-4.55) 
4 
(1.6%) 
-112 GG 
198 
(98.5%) 
NA 
 
0.720 
 
NA 
 
NA 
 
263 
(98.1%) 
NA 
 
0.950 
 
NA 
 
NA 
 
253 
(98.1%) 
(Novel) GA 
3 
(1.5%) 
    
5 
(1.9%) 
 
0.96 
(0.28-3.36) 
  
5 
(1.9%) 
 AA 
0 
(0.0%) 
    
0 
(0.0%) 
    
0 
(0.0%) 
IVS1+18 GG 
139 
(69.2%) 
0.760 
 
0.009 
 
0.630 
 
0.004 
 
172 
(64.2%) 
.200 
 
0.027 
 
0.490 
 
0.007 
 
173 
(67.0%) 
(rs3819025) GA 
54 
(26.9%) 
 
.80 
(0.53-1.20) 
  
87 
(32.5%) 
 
1.04 
(0.72-1.50) 
  
84 
(32.6%) 
 AA 
8 
(4.0%) 
1.06 
(0.74-1.51) 
9.96 
(1.23-80.56) 
.91 
(0.61-1.35) 
10.65 
(1.32-85.89) 
9 
(3.3%) 
1.24 
(0.89-1.73) 
9.05 
(1.13-72.21) 
1.14 
(0.79-1.63) 
8.93 
(1.12-70.99) 
2 
(0.4%) 
“Novel” indicates SNPs that had not been reported previously. †The positions of SNPs 
were calculated from the translation start site. Associations significant at P < 0.05 are 
shown in bold. NA, not applicable; IVS, intervening sequence.  
 
 
A Chi-square test of homogeneity with regard to allelic distributions between cases 
and controls showed significant associations with CD for one marker, rs3819025 
(“IVS1+18” hereafter; P = 0.009, 95% CI 1.23–80.56 in codominant model; P = 
0.004, 95% CI 1.32–85.89 in recessive) and with UC for three markers, rs8193036 
(“-737” hereafter; P= 0.033, 95% CI 1.02–1.74 in additive; P = 0.020, 95% CI 1.06–
2.13 in dominant), rs2275913 (“-197” hereafter; P = 0.036, 95% CI 0.40–0.97 in 
recessive), and IVS1+18G>A (P = 0.027, 95% CI 1.13–72.21 in codominant; P = 
0.007, 95% CI 1.12–70.99 in recessive). 
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4. Haplotypes, Gene-gene Interaction and Risk of IBD 
The LDs of the analyzed SNPs were calculated and plotted (Figure 3A). Single LD 
block between the G149R and IVS4+17C>T (D′ = 1.0, r2 = 0.31) was identified at 
IL23-R. Additionally, the haplotype frequencies were calculated and both protective 
(H1) and risk (H2) haplotypes. The H2 haplotype showed a significant associattion 
with CD (P = 0.003) and UC (P = 0.005) (Table 9). One LD block was identified at 
IL-17A; -197 of IL-17A showed an association only with UC was located on the same 
strong LD block with rs8193037 (“-121” hereafter) and IVS1+18 (D′ = 0.864, r2 = 
0.09 between -197 and -121; D′ = 0.895, r2 = 0.142 between -197 and IVS1+18; D′ = 
1.0, r
2 
= 0.033 between -121 and IVS1+18). Furthermore, the haplotype frequencies 
of IL-17A were calculated but no correlation was observed between haplotype 
patterns and disease susceptibility to CD or UC (data not shown).
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Figure 3. Genetic analysis of IL-23R and IL-17A in IBD. (A) LD and haplotype block 
structures of IL-23R and IL-17A for the combined case-control dataset obtained via 
Haploview 4.1 analysis. The upper bars represent SNPs and the physical distances 
between them. The numbers within the squares indicate LD coefficient D′ values 
between respective SNPs (only LD values < 100% are reported). Dark colors indicate 
high LD and light colors indicate low LD. The SNPs are ordered according to their 
position in the gene, the direction of transcription is shown above, and internal 
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references are used for polymorphisms not present in dbSNP. (B) Odds ratios for UC 
with increasing protective (G149R or Q3H) or risk (IVS1+18A, -877G, or -737T) 
alleles in IL-23R or IL-17A, respectively. The x-axis shows the accumulations of 
corresponding alleles. (C) Odds ratios for UC with protective (IVS4+17, G149R or 
Q3H) alleles from IL-23R without and with risk (-121, IVS1+18, -877, or -737) alleles 
from IL-17A. A dominant model was applied to (B) and (C), and the IL-23R gene is 
considered as dominant.
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Table 9. Haplotype Frequencies of IL-23R among cases and controls and their 
association with IBD 
Gene Haplotype G149R IVS4+17C>T 
CD UC 
Frequency 
Case, Control 
ratios  
P value Frequency 
Case, Control 
ratios  
P value 
IL-23R 
H1 G C 0.938 0.958, 0.923 0.219 0.929 0.935, 0.922 0.441 
H2 A C 0.042 0.033, 0.064 0.005 0.046 0.028, 0.064 0.005 
Haploview software version 4.1 (Broad Institute of MIT and Harvard, Cambridge, MA, USA) was used 
to analyze the linkage disequilibrium (LD) structure and to test for associations between haplotypes and 
IBD. Haplotypes with a frequency > 3% are numbered in order of frequency. Associations significant at 
P < 0.05 are shown in bold. 
 
 
Significant dose-dependent increases in the frequencies of protective (IL-23R) or 
risk (IL-17A) alleles were found in UC patients compared to wild type patients 
(Figure 3B) but the increases were not significant for CD (data not shown). 
Consequently, cumulative risk alleles of IL-17A diminished the protective OR of IL-
23R in IBD patients, which indicates that as the number of risk allele of IL-17A 
increases, so does the additive risk for UC (Figure 3C). 
The large number of IBD candidate genes allowed us to evaluate gene-gene 
interactions among susceptibility genes to gain insight into disease pathology and to 
help predict disease risk. As further evidence of the synergistic effect of the genes in 
this pathway in the development of IBD, a significant statistical gene-gene interaction 
between Q3H in IL-23R and IVS1+18G>A in IL-17A was observed in UC (P 
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interaction = 0.003 in codominant model; P interaction = 0.003 in dominant model; P 
interaction = 0.045 in recessive model; Table 10) but not in CD (Table 11). These 
data suggest that there is a gene dosage effect on the IL23R risk associations of UC 
patients who also carry other genetic variants within IL-17A. 
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Table 10. Synergistic interactions between IL-23R and IL-17A genotypes in UC  
UC 
IVS1+18 
Codominant Dominant Recessive 
Q3H GG GA AA GG GA AA GG GA AA 
GG 
 
1.00 
 
2.21 
(1.21-4.01) 
 
1.00 
 
2.21 
(1.21-4.01) 
 
1.00 
 
1.10 
(0.74-1.65) 
 
GT 
 
1.73 
(1.09-2.75) 
1.04 
(0.59-1.83) 
    
0.74 
(0.41-1.33) 
0.56 
(0.25-1.27) 
0.00 
 
TT 
 
0.98 
(0.52-1.87) 
0.75 
(0.32-1.77) 
0.00 
 
1.50 
(0.97-2.31) 
0.96 
(0.57-1.60) 
6.42 
(0.73-56.39) 
   
Interactive 
P value 
0.003 
 
  
0.003 
 
  
0.045 
 
  
Associations significant at P < 0.05 are shown in bold. 
 
 
Table 11. Synergistic interactions between IL-23R and IL-17A genotypes in CD 
CD 
IVS1+18 
Codominant Dominant Recessive 
Q3H GG CA AA GG CA AA GG CA AA 
GG 
 
1.00 
 
1.38 
(0.69-2.73)  
3.28 
(0.29-37.14) 
1.00 
  
1.38 
(0.69-2.73) 
 3.28 
(0.29-37.14)  
1.00 
  
0.78 
(0.50-1.23) 
7.15 
(0.85-60.22) 
GT 
 
1.81  
(1.11-2.96) 
0.90 
(0.48-1.68) 
       
TT 
 
1.04 
(0.53-2.05) 
0.96 
(0.41-2.28)  
 3.28 
(0.29-37.14) 
 1.57 
(0.99-2.49)  
0.92 
(0.52-1.60) 
 9.83 
(1.15-84.21) 
0.75 
(0.40-1.41)  
0.70 
(0.31-1.59) 
2.38 
(0.21-26.61) 
Interactive 
P value 
0.150   0.130   0.830   
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Our groups previously genotyped 8 SNPs (rs11889341, rs7574865, rs8179673, 
rs6752770, rs925847, rs10168266, rs10181656, and rs11685878) in the STAT4 gene 
in IBD patients and controls and reported the association of STAT4 gene (rs11889341, 
P = 0.029; rs925847, P = 0.023; rs10168266, P = 0.044) with IBD.
30
 In addition, 
weak epistasis between the CD-protective IL23-R variant rs11209026 with several 
STAT4 SNPs in Caucasian was demonstrated.
34
 Given that IL-23 activates not only 
STAT3 but also to a lesser degree STAT4, It next was investigated potential gene-
gene interaction (epistasis) with the IBD susceptibility gene IL-23R and IL-17A. As 
further evidence of the synergistic effect of the genes in this pathway in the 
development of IBD, a significant statistical gene-gene interaction between IL-23R 
and STAT4 was observed in UC (between Q3H and rs6752770: P interaction = 0.005 
in codominant model; P interaction = 0.010 in dominant model; P interaction = 0.010 
in recessive model; between Q3H and rs11685878: P interaction = 0.003 in 
codominant model; P interaction = 0.020 in dominant model; P interaction = 0.048 in 
recessive model; Table 12) in UC (Table 12) but not in CD (data not shown).  
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Table 12. Gene-gene interactions between IL-23R and STAT4 genotypes in UC 
UC 
rs6752770 
Codominant Dominant Recessive 
Q3H AA AG GG AA AG GG AA AG GG 
GG 
1.00 
 
0.34 
(0.18-0.64) 
0.61 
(0.14-2.55) 
1.00 
  
0.34 
(0.18-0.64) 
0.61  
(0.14-2.55) 
1.00 
  
0.58  
(0.38-0.89) 
1.01  
(0.39-2.58) 
GT 
0.71  
(0.43-1.17) 
0.67  
(0.36-1.24) 
1.06  
(0.29-3.84) 
      
TT 
0.35  
(0.17-0.73) 
0.80  
(0.35-1.79) 
0.00 
 
0.61  
(0.38-0.97) 
0.71  
(0.41-1.23) 
0.71  
(0.22-2.24) 
0.42  
(0.21-0.83)  
0.96  
(0.45-2.05) 
0.00 
 
Interactive 
P value 
0.005   0.010   0.010   
 
 
UC 
rs11685878 
Codominant Dominant Recessive 
Q3H CC CT TT CC CT TT CC CT TT 
GG 
1.00 
 
0.52  
(0.27-1.00) 
0.70  
(0.31-1.57) 
1.00 
  
0.52  
(0.27-1.00) 
0.70  
(0.31-1.57) 
1.00 
  
0.77 
(0.50-1.19) 
1.08  
(0.60-1.95) 
GT 
0.60  
(0.31-1.18) 
0.73 
(0.40-1.33) 
1.19  
(0.49-2.86) 
      
TT 
0.23 
(0.09-0.63) 
0.77  
(0.35-1.72) 
0.64  
(0.17-2.42) 
0.47  
(0.26-0.88) 
0.74  
(0.42-1.31) 
1.02  
(0.46-2.23) 
0.29  
(0.11-0.72) 
0.92  
(0.44-1.89) 
0.78  
(0.22-2.80) 
Interactive 
P value 
0.034   0.020   0.048   
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A significant statistical gene-gene interaction was observed between -444 in IL-17A 
and rs6752770 in STAT4 (P interaction = 0.040 in codominant model; P interaction = 
0.020 in dominant model), between -197 in IL-17A and rs11889341 in STAT4 (P 
interaction = 0.035 in codominant model; P interaction = 0.022 in codominant model; 
P interaction = 0.142 in recessive model), between -197 in IL-17A and rs7574865 in 
STAT4 (P interaction = 0.022 in codominant model), between -197 in IL-17A and 
rs8179673 in STAT4 (P interaction = 0.017 in codominant model; P interaction = 0.041 
in recessive model), between -197 in IL-17A and rs10168266 in STAT4 (P interaction = 
0.038 in codominant model; P interaction = 0.042 in dominant model; P interaction = 
0.041 in recessive model), between -197 in IL-17A and rs10181656 in STAT4 (P 
interaction = 0.021 in codominant model; P interaction = 0.045 in recessive model), 
between -197 in IL-17A and rs11685878 in STAT4 (P interaction = 0.018 in recessive 
model), between IVS1+18 in IL-17A and rs11889341 in STAT4 (P interaction = 0.003 
in codominant model; P interaction = 0.004 in dominant model), and between IVS1+18 
in IL-17A and rs10168266 in STAT4 (P interaction = 0.015 in codominant model; P 
interaction = 0.021 in dominant model) in CD (Table 13).
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Table 13. Gene-gene interactions between IL-17A and STAT4 genotypes in CD 
CD 
rs6752770 
Codominant Dominant Recessive 
-444 AA AG GG AA AG GG AA AG GG 
AA 
1.00 
 
2.08 
(0.92-4.69) 
0.47 
(0.05-4.43) 
1.00 
  
2.08 
(0.92-4.69) 
0.47  
(0.05-4.43) 
1.00 
  
0.97  
(0.61-
1.56) 
1.29  
(0.51-
3.23) 
AG 
1.75 
(0.94-3.25) 
1.15  
(0.58-2.29) 
2.80  
(0.89-8.86) 
      
GG 
1.93  
(0.94-3.97) 
1.08 
(0.44-2.66) 
 
1.81  
(1.01-3.24) 
1.13  
(0.60-2.15) 
2.80  
(0.89-8.86) 
1.34 
(0.74-2.40)  
0.75 
(0.34-
1.66) 
 
Interactiv
e 
P value 
0.040   0.020   0.280   
 
CD 
rs10168266 
Codominant Dominant Recessive 
-197 GG AG AA GG AG AA GG AG AA 
GG 
1.00 
 
1.10  
(0.51-2.35) 
3.97  
(0.72-21.80) 
1.00 
  
1.10  
(0.51-2.35) 
3.97  
(0.72-21.80) 
1.00 
  
0.73  
(0.46-1.17) 
0.80  
(0.32-2.00) 
GA 
1.97  
(1.07-3.63) 
1.08  
(0.57-2.06) 
0.63  
(0.18-2.21) 
      
AA 
1.10  
(0.50-2.43) 
1.39  
(0.66-2.93) 
0.26  
(0.03-2.31) 
1.68  
(0.95-2.97) 
1.18  
(0.66-2.13) 
0.50  
(0.16-1.50) 
0.74 
(0.37-1.50)  
0.94 
(0.49-1.81) 
0.18 
(0.02-1.51) 
Interactive 
P value 
0.038   0.042   0.220   
IVS1+18 GG AG AA GG AG AA GG AG AA 
GG 
1.00 
 
1.12  
(0.69-1.84) 
0.44 
(0.15-1.28) 
1.00 
  
1.12  
(0.69-1.84) 
0.44  
(0.15-1.28) 
1.00 
  
0.82  
(0.54-1.23) 
0.65  
(0.29-1.47) 
GA 
1.15 
 (0.65-2.05) 
0.41 
(0.20-0.85) 
1.53  
(0.39-5.93) 
      
AA 
4.89  
(0.53-44.86) 
  
1.26  
(0.72-2.20) 
0.51 
(0.26-1.01) 
1.53  
(0.39-5.93) 
4.66  
(0.51-42.40) 
  
Interactive 
P value 
0.015   0.021   0.280   
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CD 
rs11889341 
Codominant Dominant Recessive 
-197 CC CT TT CC CT TT CC CT TT 
GG 
1.00 
 
1.18  
(0.56-2.51) 
6.48  
(0.69-60.88) 
1.00 
  
1.18 
(0.56-2.51) 
6.48  
(0.69-60.88) 
1.00 
  
0.81 
(0.51-1.29) 
0.92  
(0.36-2.32) 
GA 
1.90  
(1.04-3.49) 
1.16 
(0.61-2.21) 
0.81  
(0.25-2.61) 
      
AA 
1.22  
(0.56-2.62) 
1.47  
(0.68-3.18) 
0.20  
(0.02-1.70) 
1.67 
(0.94-2.94) 
1.26  
(0.70-2.26) 
0.54  
(0.19-1.52) 
0.84 
(0.43-1.66)  
1.01 
(0.51-2.02) 
0.14 
(0.02-1.14) 
Interactive 
P value 
0.035   0.022   0.140   
IVS1+18 CC CT TT CC CT TT CC CT TT 
GG 
1.00 
 
1.21 
(0.74-1.99) 
0.36  
(0.13-1.04) 
1.00 
  
1.21  
(0.74-1.99) 
0.36  
(0.13-1.04) 
1.00 
  
0.87  
(0.58-1.32) 
0.63  
(0.28-1.42) 
GA 
1.10  
(0.62-1.95) 
0.43  
(0.21-0.88) 
3.09  
(0.58-16.44) 
      
AA 
4.94 
(0.54-45.28) 
  
1.20 
(0.69-2.10) 
0.53 
(0.27-1.05) 
3.09  
(0.58-16.44) 
4.78  
(0.53-43.51) 
  
Interactive 
P value 
0.003   0.004   0.290   
 
 
CD 
rs7574865 
Codominant Dominant Recessive 
-197 GG GT TT GG GT TT GG GT TT 
GG 
1.00 
 
1.30  
(0.62-2.74) 
4.30  
(0.78-23.83) 
1.00 
  
1.30 
(0.62-2.74) 
4.30 
(0.78-23.83) 
1.00 
  
0.76  
(0.48-1.21) 
1.29  
(0.56-2.98) 
GA 
2.17  
(1.13-4.17) 
1.11  
(0.58-2.14) 
1.55  
(0.55-4.32) 
      
AA 
1.17  
(0.53-2.57) 
1.82  
(0.80-4.16) 
0.47  
(0.12-1.84) 
1.77 
(0.97-3.24) 
1.28  
(0.70-2.36) 
0.98  
(0.41-2.33) 
0.75  
(0.38-1.51)  
1.17  
(0.56-2.45) 
0.30  
(0.08-1.13) 
Interactive 
P value 
0.022   0.058   0.056   
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CD 
rs8179673 
Codominant Dominant Recessive 
-197 TT CT CC TT CT CC TT CT CC 
GG 
1.00 
 
1.30  
(0.62-2.74) 
4.30  
(0.78-23.83) 
1.00 
  
1.30 
(0.62-2.74) 
4.30 
(0.78-23.83) 
1.00 
  
0.77  
(0.48-1.22) 
1.30 
(0.56-2.99) 
GA 
2.18  
(1.14-4.20) 
1.13  
(0.59-2.15) 
1.55  
(0.55-4.32) 
      
AA 
1.10  
(0.50-2.44) 
1.92  
(0.85-4.36) 
0.47  
(0.12-1.84) 
1.75  
(0.95-3.20) 
1.31  
(0.72-2.41) 
0.98  
(0.41-2.33) 
0.71 
(0.35-1.44)  
1.24 
(0.60-2.57) 
0.30 
(0.08-1.13) 
Interactive 
P value 
0.017   0.065   0.041   
 
CD 
rs10181656 
Codominant Dominant Recessive 
-197 CC CG GG CC CG GG CC CG GG 
GG 
1.00 
 
1.30  
(0.62-2.74) 
4.30  
(0.78-23.83) 
1.00 
  
1.30  
(0.62-2.74) 
4.30 
(0.78-23.83) 
1.00 
  
0.79  
(0.50-1.26) 
1.31  
(0.57-3.03) 
GA 
2.14  
(1.11-4.12) 
1.16  
(0.61-2.21) 
1.55 
(0.55-4.32) 
      
AA 
1.10  
(0.50-2.44) 
1.92  
(0.85-4.36) 
0.47 
(0.12-1.84) 
1.72  
(0.94-3.15) 
1.34  
(0.73-2.45) 
0.98  
(0.41-2.33) 
0.72  
(0.36-1.46) 
1.26  
(0.61-2.61) 
0.31  
(0.08-1.15) 
Interactive 
P value 
0.021   0.071   0.045   
 
 
A significant statistical gene-gene interaction was observed between -737 in IL-17A 
and rs6752770 in STAT4 (P interaction = 0.005 in dominant model; P interaction = 
0.002 in recessive model), between -444 in IL-17A and rs7574865 in STAT4 (P 
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interaction = 0.043 in dominant model), between -444 in IL-17A and rs8179673 in 
STAT4 (P interaction = 0.045 in recessive model), between -444 in IL-17A and 
rs10181656 in STAT4 (P interaction = 0.014 in codominant model; P interaction = 
0.043 in recessive model), between -197 in IL-17A and rs11889341 in STAT4 (P 
interaction = 0.031 in dominant model), between -197 in IL-17A and rs7574865 in 
STAT4 (P interaction = 0.022 in codominant model; P interaction = 0.035 in dominant 
model), between -197 in IL-17A and rs8179673 in STAT4 (P interaction = 0.019 in 
codominant model; P interaction = 0.026 in dominant model), between -197 in IL-
17A and rs925847 in STAT4 (P interaction = 0.035 in dominant model), between -197 
in IL-17A and rs10181656 in STAT4 (P interaction = 0.025 in codominant model; P 
interaction = 0.035 in recessive model), between IVS1+18 in IL-17A and rs11889341 
in STAT4 (P interaction = 0.023 in codominant model; P interaction = 0.042 in 
dominant model) in UC (Table 14). 
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Table 14. Gene-gene interactions between IL-17A and STAT4 genotypes in UC 
UC 
rs6752770 
Codominant Dominant Recessive 
-737 AA AG GG AA AG GG AA AG GG 
CC 
1.00 
 
0.65  
(0.36-1.17) 
2.54 
(0.48-13.53) 
1.00 
  
0.65  
(0.36-1.17) 
2.54  
(0.48-13.53) 
1.00 
  
0.57 
(0.38-0.86) 
1.01  
(0.36-2.79) 
CT 
1.69 
 (1.04-2.74) 
0.83  
(0.47-1.48) 
0.81  
(0.21-3.15) 
      
TT 
0.74  
(0.32-1.74) 
4.74  
(1.30-17.22) 
0.68  
(0.11-4.18) 
1.48  
(0.93-2.33) 
1.11 
(0.65-1.90) 
0.76  
(0.25-2.31) 
0.58  
(0.25-1.30) 
3.66  
(1.03-13.03) 
0.52  
(0.09-3.18) 
Interactive 
P value 
0.005   0.230   0.002   
 
UC 
rs7574865 
Codominant Dominant Recessive 
-444 GG GT TT GG GT TT GG GT TT 
AA 
1.00 
 
1.00  
(0.50-1.98) 
1.16 
(0.24-5.66) 
1.00 
  
1.00  
(0.50-1.98) 
1.16 
(0.24-5.66) 
1.00 
  
1.26  
(0.83-1.90) 
1.22  
(0.55-2.69) 
AG 
0.82  
(0.44-1.56) 
1.18  
(0.63-2.23) 
1.05  
(0.39-2.80) 
      
GG 
0.53 
(0.23-1.23) 
1.39 
(0.61-3.18) 
0.17 
(0.04-0.87) 
0.74  
(0.40-1.36) 
1.23  
(0.67-2.26) 
0.61 
(0.26-1.43) 
0.60 
(0.29-1.25) 
1.58  
(0.78-3.22) 
0.20  
(0.04-0.93) 
Interactive 
P value 
0.140   0.360   0.043   
-197 GG GT TT GG GT TT GG GT TT 
GG 
1.00 
 
2.47 
(1.29-4.75) 
3.58 
(0.65-19.71) 
1.00 
  
2.47  
(1.29-4.75) 
3.58  
(0.65-19.71) 
1.00 
  
1.31  
(0.86-1.98) 
1.22 
(0.54-2.77) 
GA 
2.00 
(1.07-3.74) 
1.62  
(0.89-2.93) 
1.43  
(0.53-3.87) 
      
AA 
0.86  
(0.39-1.90) 
1.77  
(0.80-3.91) 
0.39  
(0.10-1.52) 
1.55  
(0.87-2.76) 
1.66 
(0.94-2.91) 
0.89  
(0.39-2.04) 
0.59  
(0.29-1.19) 
1.21 
(0.59-2.45) 
0.27 
(0.07-0.99) 
Interactive 
P value 
0.026   0.035   0.190   
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UC 
rs8179673 
Codominant Dominant Recessive 
-444 TT CT CC TT CT CC TT CT CC 
AA 
1.00 
 
1.05  
(0.53-2.10) 
1.20  
(0.25-5.85) 
1.00 
  
1.05  
(0.53-2.10) 
1.20 
(0.25-5.85) 
1.00 
  
1.28  
(0.84-1.94) 
1.23  
(0.56-2.72) 
AG 
0.85  
(0.45-1.62) 
1.22  
(0.65-2.29) 
1.08  
(0.40-2.90) 
      
GG 
0.55 
(0.24-1.27) 
1.44 
(0.63-3.30) 
0.18 
(0.04-0.90) 
0.76  
(0.41-1.41) 
1.27  
(0.69-2.33) 
0.63 
(0.27-1.49) 
0.61 
(0.29-1.27) 
1.60  
(0.78-3.27) 
0.20  
(0.04-0.94) 
Interactive 
P value 
0.150   0.430   0.045   
-197 TT CT CC TT CT CC TT CT CC 
GG 
1.00 
 
2.61 
(1.35-5.02) 
3.71  
(0.67-20.42) 
1.00 
  
2.61 
(1.35-5.02) 
3.71 
(0.67-20.42) 
1.00 
  
1.33 
(0.87-2.02) 
1.23 
(0.54-2.80) 
GA 
2.08  
(1.11-3.92) 
1.67 
(0.92-3.03) 
1.48  
(0.55-4.01) 
      
AA 
0.89  
(0.40-1.97) 
1.83 
(0.83-4.05) 
0.40  
(0.10-1.58) 
1.60  
(0.89-2.87) 
1.71  
(0.97-3.01) 
0.92  
(0.40-2.12) 
0.59  
(0.29-1.21) 
1.22  
(0.60-2.48) 
0.27  
(0.07-1.00) 
Interactive 
P value 
0.019   0.026   0.190   
 
UC 
rs10181656 
Codominant Dominant Recessive 
-444 CC CG GG CC CG GG CC CG GG 
AA 
1.00 
 
1.00  
(0.50-1.98) 
1.16 
(0.24-5.66) 
1.00 
  
1.00  
(0.50-1.98) 
1.16 
(0.24-5.66) 
1.00 
  
1.25  
(0.83-1.90) 
1.22  
(0.55-2.69) 
AG 
0.82 
(0.43-1.56) 
1.18 
(0.63-2.21) 
1.05  
(0.39-2.80) 
      
GG 
0.53  
(0.23-1.23) 
1.39  
(0.61-3.18) 
0.17  
(0.04-0.87) 
0.74 
(0.40-1.36) 
1.23 
(0.67-2.25) 
0.61  
(0.26-1.43) 
0.60  
(0.29-1.25) 
1.58  
(0.77-3.23) 
0.20  
(0.04-0.93) 
Interactive 
P value 
0.014   0.360   0.043   
-197 CC CG GG CC CG GG CC CG GG 
GG 
1.00 
 
2.47  
(1.29-4.75) 
3.58  
(0.65-19.71) 
1.00 
  
2.47  
(1.29-4.75) 
3.58 
(0.65-19.71) 
1.00 
  
1.30 
(0.86-1.98) 
1.22  
(0.54-2.77) 
GA 
2.01  
(1.07-3.78) 
1.62 
(0.89-2.92) 
1.43 
(0.53-3.87) 
      
AA 
0.86 
(0.39-1.90) 
1.77  
(0.80-3.91) 
0.39  
(0.10-1.52) 
1.55  
(0.87-2.77) 
1.65  
(0.94-2.90) 
0.89  
(0.39-2.04) 
0.59  
(0.29-1.19) 
1.21  
(0.59-2.45) 
0.27  
(0.07-0.99) 
Interactive 
P value 
0.025   0.035   0.190   
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UC 
rs11889341 
Codominant Dominant Recessive 
-197 CC CT TT CC CT TT CC CT TT 
GG 
1.00 
 
2.38  
(1.24-4.55) 
5.37  
(0.57-50.18) 
1.00 
  
2.38  
(1.24-4.55) 
5.37 
(0.57-50.18) 
1.00 
  
1.53  
(1.01-2.32) 
0.93  
(0.38-2.29) 
GA 
1.63  
(0.91-2.94) 
1.81 
(1.01-3.23) 
0.81 
 (0.27-2.43) 
      
AA 
0.90 
(0.41-1.93) 
1.34  
(0.64-2.83) 
0.34 
(0.07-1.68) 
1.38 
(0.80-2.39) 
1.66  
(0.97-2.86) 
0.60 
(0.23-1.53) 
0.68  
(0.34-1.37) 
1.02  
(0.52-2.00) 
0.26  
(0.05-1.24) 
Interactive 
P value 
0.120   0.031   0.610   
IVS1+18 CC CT TT CC CT TT CC CT TT 
GG 
1.00 
 
1.65 
1.03-2.63) 
0.39  
(0.15-1.05) 
1.00 
  
1.65 
(1.03-2.63) 
0.39 
(0.15-1.05) 
1.00 
  
1.45 
(0.99-2.11) 
0.70  
(0.32-1.51) 
GA 
1.02  
(0.58-1.80) 
1.17 
(0.68-2.04) 
3.34  
(0.65-17.07) 
      
AA 
2.23  
(0.20-25.07) 
  
1.05 
(0.60-1.84) 
1.38  
(0.81-2.37) 
3.34  
(0.65-17.07) 
2.21  
(0.20-24.72) 
  
Interactive 
P value 
0.023   0.042   0.140   
 
UC 
rs925847 
Codominant Dominant Recessive 
-197 TT CT CC TT CT CC TT CT CC 
GG 
1.00 
 
0.41 
(0.18-
0.96) 
0.31  
(0.12-
0.81) 
1.00 
  
0.41 
(0.18-
0.96) 
0.31  
(0.12-
0.81) 
1.00 
  
0.59  
(0.36-
0.97) 
0.75  
(0.42-1.33) 
GA 
0.54 
(0.22-
1.31) 
0.38  
(0.17-
0.86) 
0.72 
(0.28-
1.80) 
      
AA 
0.43 
(0.15-
1.27) 
0.19  
(0.08-
0.50) 
0.50  
(0.15-
1.63) 
0.51 
(0.22-
1.18) 
0.31  
(0.14-
0.69) 
0.65 
(0.27-
1.57) 
0.65  
(0.27-
1.58) 
0.29 
(0.14-
0.60) 
0.75 
 (0.27-2.08) 
Interactiv
e 
P value 
0.130   0.035   0.510   
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5. Allelic-specific Binding Activities of Nuclear Proteins in the IL-17A 
Promoter Region and their Effects on Gene Expression 
Levels of IL-17A and STAT4 mRNA in colonic mucosa were measured by real-time 
RT-PCR. IL-17A expression was elevated in the colonic mucosa of IBD patients, as 
reported earlier
40-42
 but levels of STAT4 were not significantly different between cases 
and controls. (Figure 4).  
 
 
 
Figure 4. Expressions levels of IL-17A mRNA in the colonic mucosa of IBD patients. 
Elevated expression of IL-17A was observed in the colonic mucosa of IBD patients. 
RNA was extracted from mucosal biopsies from healthy donors (n = 9) and IBD 
patients (n = 9) and IL-17A expression was quantified by real-time RT-PCR and 
normalized to GAPDH expression. The horizontal lines represent the median values 
for each group.
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 Gene expression is regulated by a complex of transcriptional activator or inhibitor 
with transcriptional machinery and can be influenced by sequence variations in 
promoter regions.
43
 Potential transcription factor binding sites in IL17A promoter 
region were identified by the TFSEARCH program 
(http://www.cbrc.jp/research/db/TFSEARCH) based on the TRANSFAC databases
44
 
with a threshold of over 80. putative T3R-B1 and RORE site in -877, Oct-1 site in -
737, C/EBP-d in -444, and were identified. No known SNPs were found within the 
TFs binding sites of IL-17A promoter (Figure 5).  
45 
 
 
 
 
Figure 5. Structure of the putative human IL-17 promoter. SNPs were indicated. No 
known SNPs were found within the binding sites of transcription factors. The 
predicted transcription factor binding sites (box) of the IL-17 promoter are indicated. 
The variation locus (underlined bold italics), CpG sites (yellow shaded) and 
translation starting point (+1) are also shown. 
*
Novel SNP.
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 EMSA was performed to investigate whether the allelic differences between the risk 
(-877G, -737T, -444A, and -197G) and the non-risk alleles of IL-17A are attributable 
to their binding activities for nuclear proteins from Jurkat cells, which were activated 
with anti-CD3/anti-CD28 mAb, and were stimulated with tumor growth factor β, IL-
6, IL-23 to induce IL-17A. As shown in Figure 6A, a higher level of protein binding 
to the risk alleles than to the non-risk alleles was detected using EMSA, supporting 
the roles of the risk alleles in IL-17A gene expression. However, a protein binding to 
the -197 sites was not detected. 
47 
 
 
 
 
 
Figure 6. Preferential binding of the transcription factor complex to the risk alleles of 
IL-17A. (A) Electrophoretic mobility shift assays were used to determine the pattern 
of nuclear protein binding to major and minor allele probes. Nuclear extract was 
obtained from activated Jurkat cells incubated for 2 hr in media with IL-23 (10 
ng/μL), TGF-β (10 ng/μL), and IL-6 (10 ng/μL) after activation with CD3 (1 mg/ml) 
and CD28 (1 μg/ml). Nuclear extracts from Jurkat cells were incubated with biotin-
labeled oligonucleotide probes containing risk or no risk alleles of high frequency. 
Asterisks indicate the risk alleles. (B) A supershift assay was performed using 
antibodies against RORC. Competition experiments were performed using a 200-fold 
molar excess of the cold probe. The result of one representative experiment (out of 
five that produced identical results) are shown. 
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To determine the sequence specificity of the DNA-protein complex, competition 
experiments were performed using cold probes (Figure 6B). The bands were 
competed against a 200-fold molar excess of unlabeled probe, which clearly 
demonstrate specific binding of the probes to the nuclear proteins. Moreover, we 
investigated the binding of RORC(human ortholog of RORt), a master 
regulator of IL-17, to the TF complexes.
45
 Antibodies against RORC (human 
ortholog of RORt) supershifted the DNA-protein complex, indicating that the 
observed DNA-protein complexes formed due to specific DNA-protein 
interactions (Figure 6B).  
Although several IL-17A polymorphisms have been characterized at least partially, 
no biological explanation has been provided for the observed associations between 
IL-17A genotypes and IBD. IL-17A mRNA levels have previously been reported to be 
elevated in the PBMCs of IBD patients.
46
 Therefore, the in vivo mRNA expression 
levels according to IL-17A variants was further evaluated by comparing the 
expression patterns of IL-17A in PBMCs of normal and IBD patients using 
quantitative real-time RT-PCR. In the first attempt to understand how risk alleles 
might influence IBD predisposition, it was considered to evaluate the effects of 
variants at -877, -737, -444, and -197 on different IL-17A mRNA expression levels. 
Although a large variability was found among individuals, the expressions of IL-17A 
transcripts generally higher in patients with risk alleles, variant -737T (P = 0.004) or -
444A (P = 0.016), compared to those of patients with no risk alleles (Figure 7).
49 
 
 
 
Figure 7. Analysis of IL-17A mRNA expression in PBMCs from IBD patients. IL-17A 
mRNA expression was measured using real-time PCR in PBMCs from CD and UC 
patients, and is expressed as normalized units according to RORC mRNA level. 
Controls had undetectable levels of IL-17A. Dots represent the means of triplicate 
assays, and the bars indicate the mean expression level of each group. P values were 
obtained via t- test analysis. 
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6. Associations of Aberrant Hypomethylation Status of IVS1+18 in IL-17A 
and Its Implication in IBD 
Methylation of a single CpG site in a promoter region is sufficient to reduce gene 
expression.
38
 Sequencing results in our study revealed that there is a cluster of 
putative CpG sites located near translation start codon that include many critical 
regulatory sites (Figure 5). However, the DNA methylation status of the exact CpG 
sites of IL-17A remains unknown. Thus, to identify differences in the methylation 
status of the putative CpG sites between control and IBD patients and to confirm the 
likelihood of the IVS1+18G/A mediated regulation of IL-17A, bisulfite sequencing of 
12 putative CpG sites in the IL-17A locus (-969 to -684 bp and -234 to IVS1+21) 
including the variations was performed. Interestingly, it was found that two CpG sites 
(IVS1+17 and IVS1+21) in -234 to IVS1+21 region in healthy controls were 
significantly hypermethylated but were contrarily hypomethylated in IBD patients, 
based on the results of both bisulfite DNA sequencing (Figure 8A and 9A) and 
pyrosequencing (Figure 8B and 9B). In particular, IVS1+17 was significantly less 
methylated in CD (2.9%; n = 20) and UC (4.3%; n = 21) patients than that in the 
controls (44%; n = 21) (Figure 8B) and, were tightly correlated with IVS1+18G>A 
conversion in IBD patients but not significantly correlated in controls (Figure 8C). 
It was investigated whether IVS1+18G>A conversion is correlated with IL-17A 
expression in PBMCs of IBD. A statistically significant inverse correlation was 
observed between the IL-17A mRNA levels and IVS1+18G>A conversion in IBD 
patients (Figure 8D), Based on these results, it can be proposed that in healthy 
51 
 
individuals, IL-17A expression is down-regulated by hypermethylation of CpG sites 
in the promoter region of IL-17A. 
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Figure 8. Promoter methylation status of the IL-17A promoter in IBD patients. Two 
CpG sites (IVS1+17 and IVS1+21) in the -234 to IVS1+21 region were significantly 
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hypermethylated in healthy controls but hypomethylated in IBD patients as shown by 
bisulfite DNA sequencing (A) and pyrosequencing (B). (A) Comparison of the 
methylation status of promoter CpG sites in PBMCs from healthy controls and IBD 
patients. Methylation status was analyzed using bisulfite sequencing. Black, gray, and 
white squares represent complete methylation, partial methylation, and no methylation, 
respectively. Position +1 is determinded by start codon. (B) Methylation status was 
analyzed using pyrosequencing. (C) Correlation between methylation status at 
IVS1+17C and allele types at IVS1+18 in IBD patients and health control. (D) Allele 
types at IVS1+18 and IL-17A mRNA expression levels in IBD patients. A statistically 
significant inverse correlation was observed between IL-17A mRNA levels and 
IVS1+18G>A conversion in IBD patients. Error bars indicate means SE. *P < 0.001. 
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Figure 9. Representative bisulfite sequencing and pyrosequencing data for 
quantitation of methylated CpGs in the IL-17A promoter in patient PBMC. (A) After 
bisulfite treatment, all cytosine residues were converted to thymine. The cytosine 
residues of the CpG site located at IVS1+17 and 21 are designated as “+17” and 
“+21”, respectively (B) Pyrosequencing of IVS1+17 and 21. The methylation 
percentage was calculated by comparing the magnitude of the “C” peak with that of 
the next “T” peak (blue box) subsequently read at the same nucleotide. 
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Our group reported that SNPs of STAT4 was associated with IBD susceptibility.
30
 
Thus, STAT4 mRNA expression and methylation status were also investigated (Figure 
10). Compared with STAT4, IL-17A showed dramatic differences in the promoter 
methylation between healthy control and IBD patients.  
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Figure 10. STAT4 mRNA expression and promoter methylation status of the STAT4 
promoter in patients with IBD. (A) Analysis of STAT4 transcript levels in PBMCs 
from normal (C) and IBD patients. (B) Comparison of STAT4 promoter CpG site 
(+102) methylation in PBMC from healthy control and PBMC from IBD patients. 
Methylation status was analyzed by pyrosequencing.
57 
 
7. Association of IL-17A Silencing with DNA Methylation in Jurkat cells 
To decipher whether IL-17A induction is associated with aberrant DNA methylation, 
the effects of the demethylating agent 5-Aza-dC, a DNA methyltransferase (DNMT) 
inhibitor, on IL-17A expression in Jurkat cells was tested. IL-17A transcription was 
restored nearly to stimulated level following treatment of Jurkat cells which 
initially displayed no IL-17A expression (Figure 11).  
 
 
 
 
Figure 11. IL-17A is downregulated via DNA methylation in Jurkat cell lines. Jurkat 
cells were incubated for 12 h in media with IL-23/TGF-β/IL-6, or PMA (20 nM) and 
ionomycin (2 μM), or 5-Aza-dC (400 nM) for 72-96 h after activation with CD3 (1 
mg/mL) and CD28 (1 μg/mL) for 48 hr. IL-17A mRNA levels were measured using 
quantitative real-time RT-PCR, in which RORC was used as the normalization 
control.
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 To evaluate the methylation statuses of CpG sites in the IL-17A promoter, bisulfate 
DNA sequencing and pyrosequencing analysis of 12 CpG sites at the IL-17A 
promoter region (nucleotides -969 to -684 bp and -234 to IVS1+21) including the 
variations was performed. Similar to the methylation patterns in PBMCs, CpG sites at 
-969 to -684 bp were found to be methylated extensively in Jurkat cells. 
Unexpectedly, however, CpG sites at -234 to IVS1+21 near the transcriptional start 
site were unmethylated in both the 5-Aza-dC-treated and untreated samples, 
consistent with the constant levels of IL-17A expression seen in 5-Aza-dC-treated 
Jurkat cells but in contrast to the results for PBMCs (Figure 12A and B). Although it 
was failed to explain the direct effect of IVS1+18G>A conversion on IL-17A, these 
results imply that more complicated chromatin conformation changes or other CpG 
sites may be involved in gene regulation via DNA methylation and indicate that DNA 
methylation is a critical mechanism through which IL-17A expression is regulated. 
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Figure 12. IL-17A methylation status in Jurkat cells. IL-17A methylation status analysis 
according to 5-Aza-dC treatment for 72-96 hr using pyrosequencing analysis (A) and 
bisulfite sequencing analysis (B). Black, gray, and white squares represent complete 
methylation, partial methylation, and unmethylation, respectively.  
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IV. DISCUSSION 
 
The main objective of this study was to assess the contributions of IL-23R and 
IL-17A genetic polymorphisms to IBD susceptibility and to elucidate the 
underlying mechanisms. A growing body of evidence suggests that activation of the 
IL-23/IL-17 axis, as a critical regulatory system that bridges the innate and adaptive 
arms of the immune system, is fundamentally linked to the pathogenesis of 
autoimmune diseases, including IBD.
47-49
 In this regard, recent studies in animal 
models and humans have demonstrated that Th17 cells promote intestinal 
inflammation
50
 and that IL-17 exerts multiple inflammatory effects,
51
 including the 
release of proinflammatory cytokines (IL-22, TNF-α, IL-6, and IL-8) and recruitment 
of monocytes and neutrophils.
52,53
 IL-17 is able to induce the expression of two mucin 
genes in bronchial epithelial cells
54
, and increased expression of IL-17 has been shown 
to be associated with enhanced mucin gene expression in vivo.
55
 Furthermore, recent 
reports strongly suggested that the IL-23/IL-17 axis that is associated with Th17 is 
required for the development of TNBS-colitis as well as bacterially-induced intestinal 
inflammation.
56-58
 IL-17-deficient mice are resistant to collagen-induced 
arthritis
59
 and EAE.
60
 In addition, IL-17- and IL-23-deficient mice are resistant 
to experimental glomerulonephritis.
61,62
 In sharp contrast, the inflammatory 
function of IL-17A in different types of experimental colitis models are contradictory; 
some studies have reported that in the intestinal environment, IL-17A is protective, 
61 
 
while others have reported that it is proinflammatory.
63,64
 IL-17 and IL-22 can be 
produced by non-T cells, and T cell responses may therefore not play indispensable 
roles, because IBD is inducible in T cell-deficient mice,
65
 while monocyte and 
macrophage linage cells are important mediators of UC and DSS-induced colitis
66
 and 
these cells also can produce IL-17A in inflamed colonic tissue.
15
 CD, in contrast, 
shows a particularly strong connection to Th17 inflammation; genome-wide studies 
have shown an association between polymorphisms in IL-23R and increased CD 
susceptibility as well as between single nucleotide polymorphisms in other components 
of the Th17 pathway (i.e., stat3, p40, jak2, and ccr6) and CD susceptibility.
9
 Therefore, 
IL-17 may be a key mechanistic factor that can account for the common 
features of IBD types that develop via different T cell-dependent and 
independent etiologies. IL-23 is expressed on activated myeloid cells, and a subset of 
T cells is the most potent inducer of IL-17. IL-23 functions as a terminal differentiator 
of Th17 cells, and IL-23R serves as an initial sensor of IL-23 and is therefore important 
in Th17-cell mediated autoimmune responses.
12,67
 The main objectives of this study 
were to assess the contributions of genetic variants of IL-23R and IL-17A to genetic 
susceptibility to IBD and to elucidate their potential underlying mechanisms. 
Although the exact mechanisms via which IL-23R modulates IBD susceptibility are 
not yet clear, the key role of IL-23 in IBD has been demonstrated by recent genetic 
studies in which genetic variants in the IL-23R gene were found to be associated with 
IBD.
10,20-23
 Although candidate SNPs of IL-23R in Caucasian populations, including 
rs11209026, are not present as polymorphisms in Asians, including Japanese and 
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Koreans, intronic SNPs at intron 5 and in an intergenic region of IL-23R were recently 
reported to be associated with CD in the Korean population.
20,68
 These results suggest 
that there are ethnic differences in this disease, and that entire exons of IL-23R need to 
be completely investigated in Asian population. Therefore, it was considered to 
identify new susceptible genetic SNPs of IL-23R in the Korean population through 
whole exon and junction instead of using common tag SNPs. Although rs11209026 
was not polymorphic in either our Korean IBD patients or our healthy controls, that is 
different from Caucacian, it was found that the two novel SNPs, G149R (protective in 
CD and UC) and IVS4+17C>T (risk in UC) located in exon 4 showed significant 
associations with IBD development. It is interesting that the protective arginine 149 
allele was present in ~13% of controls, 4% of CD patients, and 15% of UC patients in 
our study, whereas the protective glutamine 381 allele is known to present in ~7% of 
controls, ~2-4% of CD cases, and ~4% of UC in Caucasian populations.
10,69 However, 
the odds ratio of G149R in CD or UC is similar to that in Caucacian populations. Q3H 
in exon 2 of IL-23R showed a protective effect against UC. Furthermore, pairwise 
analysis suggests that there is a genetic interaction between Q3H in IL-23R and 
IVS1+18G>A in IL-17A. The functional variants, glycine 149 to arginine and 
glutamine 3 to histidine, may affect the structure and the biologic function or stability 
of IL-23R, and nucleotide alteration at intron 4 (IVS4+17C>T) may alter the stability 
of mRNA. These findings support the idea that IL-23R is responsible for the 
association with IBD in both Caucacian and Asian populations even though there are 
ethnic differences in specific SNPs affecting IBD risk. Further investigations are 
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warranted to validate these results. 
IL-17A is located on 6p12.1, a genomic region reported to contain the putative 
susceptibility loci (IBD3) for IBD.
70
 IL-17A mRNA levels in PBMCs and circulating 
IL-17 levels in plasma have been reported to be increased in IBD patients.
42,46
 High 
levels of IL-17A mRNA have been detected in the mucosa of both CD and UC mucosa 
patients compared to healthy controls, and IL-17A has been shown to be produced by T 
cells or CD68
+
 macrophages in the colonic mucosa of IBD patients, leading to 
significant elevation of serum IL-17A levels, in contrast to normal individuals.
15,42,71
 
Although CD and UC are collectively referred to as IBD, it has been hypothesized that 
different pathogenic mechanisms may lead to the clinical phenotypes of these two 
diseases. CD is characterized by a more penetrating, transmural inflammation that can 
affect any tract of mucosa in the gut than UC; UC shows progressive inflammation that 
does not extend beyond the large intestine.
1,36
 These data suggest that there are subtle 
genetic and expression correlation differences of IL-17A in UC and CD and also 
provides evidence for different contributions of IL-23R and IL-17A polymorphisms to 
CD and UC although CD and UC shared some susceptibility genes in the 
epidemiologic study, concordant to immunologically different disease entities between 
UC and CD . 
In addition, this study demonstrated epistasis among IL23R, IL-17A and STAT4 
variants, certain STAT4 genotypes increased the risk for IBD in patients with the IL-
23R or IL-17A risk alleles. The requirement for STAT4-dependent cytokine regulation 
has been established for the pathogenesis of autoimmune encephalomyelitis,
72,73
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RA,
31,74
 and also IBD,
75-77
 highlighting a critical role for STAT4 in autoimmune 
diseases.
29
 Previous studies demonstrated constitutive STAT4 activation in the 
intestinal T cells of CD patients
75
 and increased expression and activation of IL-12-
induced STAT4 signaling in the mucosa of patients with UC.
76
 The interaction between 
STAT4 and IL-23R is intriguing given the fact that both of these genes are involved in 
IL-12 signaling and regulation of the Th1/Th17 cytokine balance. STAT4 pathway 
appears to be the major player in IL-12-induced Th1
78,79
 and IL-23-mediated Th17 
immune responses.
67
 However, what has not been clear is the activational status of IL-
12- or IL-23-induced STAT4 signaling in IBD, which is critical in orchestrating a 
sustained or chronic Th1 or Th17 inflammatory environment. Thus, the putative 
interaction in the context of the overall contribution of the IL-23R/IL-17A/STAT4 
genotype combination was analyzed, because this approach allows for determination of 
the extent to which the interaction contributes to IBD risk. If IL-17A was mutated, 
genetic alterations of STAT4, an upstream gene in the same pathway, could lead to 
changes in the Th17 cytokine profile. A recent study demonstrated a significant 
association of a STAT4 risk allele with overexpression of STAT4 in primary cells of 
mesenchymal origin such as osteoblasts but not in B cells.
80
 This indicates that tissue-
specific intragenic enhancers could affect STAT4 expression levels and that different 
STAT4 gene variants could have different cell type-specific effects. This line of 
reasoning is supported by a previous study that demonstrated that STAT4 isoforms 
differentially regulate Th1 cytokine production, with STAT4β promoting greater 
colonic inflammation and tissue destruction, correlating with STAT4 isoform-
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dependent expression of TNF- and GM-CSF in vitro and in vivo, but not in Th1 
expression of IFN- or Th17 expression of IL-17.77 Moreover, a previous study81 
reported that lupus patients carrying a risk variant of STAT4 showed increased 
sensitivity to IFN-, which could contribute to increased mucosal inflammation in IBD 
patients and to patient responses to immunosuppressive and immunomodulatory 
therapies. A recent in vivo study demonstrated impaired development of human Th1 
cells in patients with deficient expression of STAT4.
82
 Furthermore, several recent 
studies that investigated the genetic background of STAT4 regulation suggested a 
significant association between genetic variants of STAT4 with SLE and RA
29,31,83,84
 as 
well as SD,
33
 SSc,
29,85
 psoriasis
86
 and type-1 diabetes,
87
 indicating common genetic and 
molecular pathways in multiple autoimmune diseases.  
No nonsynonymous SNP of IL-17A is present in the NCBI SNP database, suggesting 
that regulatory polymorphisms rather than coding polymorphisms of IL-17A play a role 
in the pathophysiological processes of diseases with which IL-17A is associated. 
Moreover, a few reports have recently been published regarding the association 
between the -197 in the IL-17A promoter and the UC phenotype
88
 and between -737 
and pediatric asthma in Taiwanese children.
37
 However, it has not yet been clarified 
whether IL-17A polymorphisms truly affect the risk of IBD development or how this 
polymorphisms influence the activity and expression of IL-17A. This study is the first 
finding to explain the mechanism underlying the disease development that is associated 
with the variants of -737 and IVS1+18 in addition to variant -197. Allele -737T is 
significantly associated with a higher level of IL-17A mRNA expression in IBD 
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patients and displays a higher binding activity to transcription factor complexes as a 
kind of regulatory mechanism. Although -444 and -877 showed no significant 
association with IBD, these sites may also contribute IBD susceptibility in terms of 
binding affinity to the TF complex. RORC was recently identified as a master regulator 
of Th17 cytokine production.
38
 However, additional transcription factors (TFs) such as 
STAT3, ROR, and interferon regulatory factor 4 were reported to be involved in the 
promotion of Th17 cytokine production
39-42
 while Foxp3, Ets1, Gfi1, T-bet, and Smad3 
negatively regulate Th17.
43, 44
 Nevertheless, the mechanisms underlying the roles of 
these factors in Th17 differentiation are not entirely clear, and more studies are 
required to understand the complex regulsation of IL-17A expression. Of note, the 
variant at -197 was previously the only identified SNP explaining a possible 
association with autoimmune diseases in IBD; however, it did not show any affinity for 
TF complexes or methylation status and was located in LD with IVS1+18, an 
important positions that affected methylation status in this study. These results suggest 
that -197 may simply be a „linked SNP‟ rather than a SNP with its own functional 
consequences.  
DNA hypermethylation is strongly associated with heterochromatin and 
transcriptional silencing, and hypomethylation at CpG sites in the promoter region is a 
well-defined epigenetic phenomenon generally associated with active gene 
expression.
89
 Differential methylation of DNA has been reported for T cells at different 
stages of cell differentiation. Moreover, Th17 cells show distinct chromatin remodeling 
of the IL-17-A gene locus consistent with the production of IL-17.
90
 which is not stable 
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and is reversible through linkage with RORC.
91,92
 These epigenetic modifications 
undoubtedly serve as an important regulatory mechanism during maintenance of 
lineage commitment in T cells. Hypermethylation at a small number of clustered CpGs, 
which later spreads to neighboring CpGs, has also been shown to contribute to 
transcriptional regulation.
93,94
 The data presented in this study clearly indicate that CpG 
sites in the proximal promoter region of IL-17A in the healthy controls were 
dramatically hypermethylated with a negligible transcript level of IL-17A compared to 
that of the IBD patients. In particular, a significant polymorphism in the promoter 
region of IL-17A, IVS1+18G>A, was identified. As expected, changing a G nucleotide 
to an A at this site abrogated a DNA methylation site and induced aberrant 
hypomethylation of cytosine residues. In addition, the -121G>A in the same block with 
-197 showed a change in methylation status at CpG and recently was found to be 
polymorphic in other diseases,
24,88
 which may also influence transcription through a 
similar mechanism. Interestingly, IVS1+17C including -122C is colocalized with 5′ 
untranslated regions of the IL-17A gene that are intensively marked by permissive 
modifications, histone H3 lysine residue 4 trimethylation (H3K4me3) in Th17 cells, 
but extensively marked by repressive H3K27me3 modification in other T cell 
lineages.
90,91
 These data suggest that the irreversible hypomethylation of cytosine 
residues by IVS1+18G>A or -121G>A may create a far more highly “poised” state 
than normal for sustained expression of IL-17A through the H3K4me3 mark, which 
loosens the chromatin and recruits TFs. IVS1+18G>A including -121G>A could stably 
and irreversibly abrogate a binding site for methyl CpG binding protein that maintains 
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the epigenetic silencing of transcriptional activity. This change may also create 
potential TF–binding sites associated with genes that are independently activated by 
permissive modifications of histones in contrast to the phenotypic or developmental 
plasticity of Th17 cells.
91,92
 The alteration of methylation status by genetic change may 
sustain the transcriptional competence of IL-17A in Th17 cell or induce lineage 
transitions to other IL-17 secreting cells. Moreover, the IL-17A expression could be 
restored by 5-Aza-dC, a DNMT inhibitor that reduces DNA methylation, in Jurkat cells 
that initially showed no expression of IL-17A. This is the first demonstration that a 
change in DNA methylation of the IL-17A promoter may play a critical role in IL-17A 
expression and pathogenesis of IBD. However, contrary to expectations, the nucleotide 
IVS1+18 in Jurkat cell was cytosine, which suggests involvement of an epigenetic 
modification of RORC or an unknown upstream repression site/upstream repression 
site including a conserved noncoding sequence or changes in higher-order chromatin 
structure.
91,95,96
 Taken together, these results indicate that CpG dinucleotides and 
methylation in this region play an important role in the regulation of IL-17A 
transcription, though further research is needed to fully elucidate the exact mechanism. 
These aberrant methylations may result in increased sensitivity in IBD patients if 
intensive signals due to more sensitive IL-23R are introduced and cooperate with 
intensive transcriptional activation via modification of TF binding sites as unknown 
cis-elements (Figure 13). Genetic changes in multiple sites of the promoter can lead to 
physiological changes including epigenetic changes and may result in stringent or 
relaxed regulation of transcription. These findings shows for the first time that IL-17 
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expression is regulated by DNA methylation, which suggest novel mechanisms through 
which epigenetic change is coordinated with cis-regulation in IBD. 
 
 
 
Figure 13. Proposed model depicting the interplay of the polymorphic sites in IL-23R 
and IL-17A genes in response to IL-23-mediated signals. Hypomethylation of the IL-
17A promoter in IBD compared to that in controls leads to sustained signaling (1). In 
healthy controls, the protective allele of IL-23R is less sensitive to IL-23, but the IL-
23R risk allele in IBD patients is more sensitive (2). The strong affinity of IL-17A risk 
alleles to the TF complexes results in higher transcriptional activity of the promoter, 
which strengthens and retains the signaling in IBD patients compared to that in the 
healthy control subjects (3).
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 In summary, new associated SNPs of IL-23R and IL-17A as a susceptibility gene in 
IBD through a case-control association study were identified. The current study 
clearly demonstrates also that STAT4, IL-23R and IL-17A contributed interactively to 
susceptibility to the development of IBD. Moreover, the functional consequences of 
the IL-17A variants which have an allele-specific effect on gene expression in 
PBMCs by examining the affinities of these variants for TF complexes and effects on 
DNA methylation profiles was characterized. This study also highlights the 
hypomethylation status of IL-17A in PBMC of IBD patients in contrast to that of 
healthy controls in an attempt to elucidate the regulation of IL-17A expression by 
DNA methylation. These findings suggest that the polymorphisms of both genes in 
IL-23R/IL-17 including STAT4 affect IL-17A gene expression and are fundamentally 
associated with the etiology of IBD. In addition, these findings provide new 
mechanistic insights into the IL-23/IL-17 axis by demonstrating that genetic and 
epigenetic interactions in IL-17A gene regulation are the basis for the elevated IL-17 
expression in IBD patients, which could highlight a potential target for the treatment 
of IBD, although additional, larger multi-center replicated studies are required to 
confirm these findings. 
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V. CONCLUSION 
 
New associated SNPs of IL-23R and IL-17A associated with susceptibility to IBD 
were identified using a case-control association study. Moreover, the functions of the 
SNPs of IL-17A, which had an allele-specific effect on IL-17A expression in PBMCs, 
were characterized by examining the affinity of the variants for TF complexes and 
effects of these variants on DNA methylation profiles. This study also highlights the 
hypomethylation status of IL-17A in PBMCs of IBD patient in contrast to healthy 
controls, suggesting that IL-17A expression may be regulated by DNA methylation. 
These findings suggest that polymorphisms in both IL-23R and IL-17 genes including 
STAT4 affect IL-17A gene expression and are fundamentally connected to the etiology 
of IBD. These findings provide new mechanistic insights into the IL-23/IL-17 axis and 
indicate that genetic and epigenetic interactions among these genes contribute to 
elevated expression of IL-17A in IBD patients, which could be a potential target for 
modifying T cell development, although further, larger multi-centre replicated studies 
are required to confirm these findings. 
Genetic polymorphisms in IL-23R/IL-17 axis are essentially associated with IBD 
pathogenesis and provide new insights that genetic and epigenetic interactions are the 
basis for elevated expressions of IL-17 in IBD. This study would examine the intestinal 
inflammation physiology in IBD using genomic and epigenomic approachs, which will 
contribute to the advance in the diagnosis and treatment of various colonic disorders. 
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인터루킨 23 수용체 와 인터루킨 17A 유전자 다형성과 
염증성 장질환과의 관련성 규명 
 
 
<지도교수 김 원 호> 
 
연세대학교 대학원 의과학과 
 
김 승 원 
 
 
염증성 장질환은 만성적으로 대장에 염증을 나타내는 질환으로서 
크게 궤양성 대장염과 크론병으로 나뉜다. 최근 염증성 장질환은 
유전적, 환경적, 혹은 면역조절에 관련된 인자들의 복합적인 
상호작용에 의하여 발병하는 것으로 추정하고 있다. 염증성 장질환과 
관련하여 많은 연구가 이루어졌는데 이와 관련하여 서양에서 
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인터루킨 23 수용체(IL-23R)의 변이가 깊은 관련이 있음이 
보고되었으나 동양에서는 관련성을 확인하지 못하였다. 또한 염증에 
중요한 싸이토카인인 인터루킨 17A(IL-17A)의 변이의 관련성에 관한 
연구가 최근 보고 되었나 세부적인 기전을 포함하는 연구가 필요하다. 
본 연구에서는 IL-23R과 IL-17A의 유전학적, 후생유전학적 변화가 
염증성 장질환의 발병과 관련 여부를 조사하였다. IL-23R과 IL-17A의 
promoter와 exon을 크론병 201명, 궤양성 대장염 268명, 건강한 대조군 
258명을 대상으로 DNA sequencing과 DHPLC를 이용하여 분석하였다. 
Jurkat 세포와 말초혈액 단핵구를 in vitro assay에 이용하였다. 
전사인자의 결합력을 electro mobility shift assay를 통하여 분석하였으며 
IL-17A mRNA 발현량은 RT-PCR로 확인하였고 IL-17A promoter의 
methylation은 bisulfate sequencing과 pyrosequencing을 이용하여 
분석하였다. 그 결과 크론병에서는, IL-23R의 변이 G149R (OR; 0.32, 
95% CI 0.15-0.69), 와 IL-17A 의 변이 IVS1+18G>C (OR; 5.33, 95% CI 
1.12-25.37)가 관련 있었다. 궤양성 대장염에서는 IL-23R 의 변이 Q3H 
(OR; 0.62, 95% CI 0.38-1.00), G149R (OR; 0.41, 95% CI 0.21-0.77), 
IVS4+17C>T (OR; 2.9, 95% CI 1.21-6.99), IL-17A의 변이 -737C>T (OR; 
1.49, 95% CI 1.06-2.11), -197G>A (OR; 0.63, 95% CI 0.41-0.98), IVS1+18 
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G>C (OR; 4.47, 95% CI 0.96-20.86)가 관련되어 있었다. -877G, -737T, -
444A risk allele 들은 전사인자 복합체와 강한 결합력을 나타냈으며 
이들을 지닌 환자에서 말초혈액에서 높은 IL-17A의 발현과 상관성을 
나타냈다. 염증성 장질환이 있는 환자의 말초혈액의 IL-17A는 현저한 
DNA methylation을 나타내었고 이는 IL-17A의 발현과 IVS1+17의 
methylation 정도와 상관성을 보였다. Jurkat 세포에서의 IL-17A 의 
발현은 demethylating agent 처리시 회복됨을 확인하였다. 
결론적으로 본 연구를 통하여 염증성 장질환은 IL-23R/IL-17축과 
관계된 유전자 다형성과 깊이 연관되어 있으며 STAT4를 포함한 
이들의 유전학적, 후생유전학적 상호작용이 IL-17A의 증가의 중요한 
기전임을 밝혔다. 
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